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ABSTRACT 
 
Matthew Robert Ramsey: Regulation of the G1-S transition by cyclin-dependent kinase inhibitors 
 
“Under the direction of Norman E. Sharpless” 
 
 
 Cell cycle progression from G1 to S-phase depends on phosphorylation of pRb by complexes 
containing a cyclin (D-type or E-type) and cyclin-dependent kinase (e.g. cdk2, cdk4, or cdk6).  Growth 
arrest is achieved by activation of the Arf-p53 pathway, or through activation of Ink4 family proteins, 
which specifically inhibit the activity of cyclin D-cdk4/6 complexes.  We employed genetic and 
pharmacologic approaches to study the roles of the Ink4 family of proteins and the Arf-p53 pathway in 
regulating proliferation of cultured murine embryonic fibroblasts (MEFs) and murine tissues.  While the 
loss of the Ink4 genes p16Ink4a and p18Ink4c did not affect growth kinetics of MEFs despite an increase in 
cdk4 activity, reduction of Arf mRNA and protein through genetic inactivation or culture at 3% oxygen 
resulted in immortalization.  The decrease in Arf mRNA at 3% O2 was due to reduced mRNA stability, 
which was regulated by the 3’UTR of the Arf transcript.  However, Arf was still functional at 3% O2, as 
senescence could be induced through over-expression of oncogenic Ras, which increased Arf mRNA levels.  
In contrast to the lack of effect of p16Ink4a and p18Ink4c loss on MEFs, in vivo, germline deficiency of p16Ink4a 
and p18Ink4c resulted in increased proliferation in the intermediate pituitary and pancreatic islets of adult 
mice, and survival of p16Ink4a-/-; p18Ink4c-/- mice was significantly reduced due to aggressive pituitary 
tumors.  Compensation among the Ink4 proteins was observed both in vivo in p18Ink4c -/- mice and in MEFs 
from p16Ink4a -/-, p18Ink4c -/- or p16Ink4a -/-; p18Ink4c -/- mice.  Treatment with PD 0332991, a specific cdk4/6 
kinase inhibitor, abrogated proliferation in those compartments where Ink4-deficiency was associated with 
enhanced proliferation: islets, pituitary and B-lymphocytes, but had no effect on proliferation in other 
tissues such as the small bowel.  These data suggest that while Arf is the dominant regulator of proliferation 
in MEFs, p16Ink4a and p18Ink4c have a significant in vivo role in coordinately regulating the catalytic activity 
of cdk4/6 in specific compartments of adult mice.  In addition, these data demonstrate a novel, oxygen-
dependent mechanism of the regulation of senescence by the Ink4a/Arf locus. 
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CHAPTER 1 
THE CELL CYCLE 
 The cell is the most fundamental unit of life, and thus a great deal of effort has been spent in order to 
understand the mechanisms that regulate the activities of cells.  Essential to the continuation of life is the ability 
of one cell to divide, and thus pass on its genetic material to the next generation of life.  Consequently, it is of 
great interest to elucidate the mechanisms that a cell uses to control proliferation.  Cycling cells pass through 
four distinct phases, the first three of which are referred to as interphase: G1, the first gap phase, S or synthesis 
phase, G2, the second gap phase, and finally to mitosis, or M-phase.  Cells that are not cycling are referred to as 
quiescent, a period designated as the G0 phase of the cell cycle.  When cells exit G0, they enter the first growth 
phase, G1.  It is here that the cell spends most of the cycle, sensing the external environment, synthesizing 
proteins, and preparing for the extremely energy intensive process of DNA replication and mitosis.  Next, the 
cell enters the S-phase of the cycle, where the cell makes a second copy of its entire genome.  Cells then enter a 
short gap phase, G2 where the cell coordinates the various events required for successful entry into mitosis.  
Finally, the cell divides during the intricate process of mitosis, resulting in two daughter cells (119). 
 
Control of mitosis by cyclin-cdk complexes 
 The basic paradigms of cell cycle control can be illustrated through an investigation of the control of 
entry into mitosis.  Dividing cells contain an active complex (MPF) that is capable of driving the cell cycle in 
the absence of new protein synthesis (97, 143), however, MPF activity after first cycle requires protein 
synthesis (159).  The biochemical activity of MPF was first purified from Xenopus oocytes (158), and consists 
of two components (89), a protein kinase (42, 142), and a cyclin (41), which in complex, can phosphorylate a 
variety of substrates (90).  The kinase, cdk1 (83), has homologues in S. cerevisiae (cdc28) and S. pombe (cdc2) 
(11, 64, 120), and levels do not vary during the cell cycle (27).  The second component, cyclin B (41) or cdc13 
in S. cerevisiae (52), is cyclical in its expression (159) and requires cdk1 for its activity (111).  Cyclins were 
found to play a direct role in promoting entry into mitosis, and are destroyed at the end of M-phase (146, 149).   
The periodic activity of MPF is partially due to the periodic synthesis and degradation of cyclin proteins during 
the cell cycle (116), but is also regulated by post-translational modification. 
 During the majority of interphase, Cyclin B is continuously transported into the nucleus (110).  
However, cyclin B contains a nuclear export signal (NES), which leads to rapid export by CRM-1 (48, 172), 
keeping the localization primarily cytoplasmic during G1 and S-phases (39, 129).  During G2 and into M-phase, 
cyclin B is phosphorylated by Polo-like kinase (154) in the NES domain, which blocks its interaction with 
CRM-1 and leads to nuclear accumulation of cyclin B (48, 172).  Cdk1 is also regulated by phosphorylation, 
which is dependent on binding to cyclin B (18, 144).  Cdk1 is localized in the cytoplasm during interphase, then 
undergoes nuclear transport at mitosis when associated with cyclin B (14, 54).  Any cdk1 that is localized in the 
nucleus during interphase is kept inactive through phosphorylation by the nuclear kinase Wee1 (54) on Tyr-15 
(114, 121).  However, during mitosis, Wee1 is phosphorylated by Nim1 (19, 114, 127, 166), blocking its ability 
to inactivate cdk1.  The phosphorylation of Tyr-15 by Wee1 is removed by the phosphatase cdc25 (54), and this 
event is essential for the activity of the cyclin B-cdk1 complex (14, 40, 43).  Additional phosphorylation of 
cdk1 by Myt1 (74, 115) on Thr-14, is also required for activity. Finally, after the completion of metaphase, 
cyclin B is degraded by the anaphase promoting complex (45), keeping levels low until the end of G1 (1, 14). 
 
Regulating entry into S-phase 
 The engine that drives cells into mitosis, the catalytic activity of cyclin-cdk complexes, also controls S-
phase entry.  As in mitosis, the periodic synthesis and degradation of the cyclin subunits is responsible for 
controlling the timing of S-phase entry.  However, in contrast to M-phase, multiple cyclin-cdk pairs are active at 
the G1-S transition.  Three different cyclin-dependent kinases form active complexes at the G1-S boundary, cdk2 
(38, 155), cdk4 (98) and cdk6 (101).  Cdk4 and Cdk6 bind exclusively to the D-type cyclins (98, 101, 171), D1 
(113, 168), D2 and D3 (170), and the activity of this complex is determined by the level of cyclin D protein 
which increases during G1, peaks near the G1-S boundary, then rapidly declines (165).  Cdk2 has a broader 
range of binding partners and can bind cyclin E, cyclin A (73, 155), or the D-type cyclins D1 and D3 (171).  At 
the G1-S transition, cdk2 is most often found bound to cyclin E1 (73) or cyclin E2 (80, 174) which have their 
peak activity at the G1-S transition (80, 87, 174).   
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 The key downstream target of cyclin-cdk complexes is pRb (157), a DNA-binding nuclear 
phosphoprotein (84, 85), which exhibits cell cycle-dependent phosphorylation.  The Rb protein is hypo-
phosphorylated during G0 and G1, but is hyper-phosphorylated during S, G2, and M phases (15), and the 
majority of this phosphorylation occurs at the G1-S boundary (21, 91).  Hypo-phosphorylated pRb is complexed 
with (7, 16, 17, 36)  and inhibits transcriptional activity (3, 6, 55, 162) of E2F family transcription factors.  Both 
cyclin E-containing complexes (57) and cyclin D-containing complexes bind to and phosphorylate pRb (32, 70, 
98), which releases E2F, freeing it to activate key genes required for DNA synthesis (22, 63).  Thus, 
phosphorylation of pRb by the cyclin-cdk complexes is essential for the initiation of DNA synthesis. 
 Interestingly, it appears that the many cyclins found in the cell may share all the same functional 
abilities, but exert different effects through temporal and spatial regulation.  For example, cyclin E can drive the 
synthesis of DNA, while cyclin B, under the same experimental conditions, cannot (148).  This seemingly 
unique property may be due to the nuclear localization of cyclin E conferred by the nuclear localization signal 
(NLS) (110), which is essential for its ability to trigger DNA replication (109).  Cyclin B, on the other hand is 
normally localized in the cytoplasm until mitosis (39, 129) when it is retained in the nucleus by post-
translational modification.  However, if cyclin B is held in the nucleus before S-phase, it is capable of inducing 
DNA replication (108), indicating that spatial control of cyclins may be responsible for many of their unique 
functions.  This functional redundancy of cyclins also extends to temporal control, as cyclin D1 deficiency can 
be rescued by knock-in of cyclin E1 to the D1 locus (44), demonstrating that expression of cyclin E1 in place of 
cyclin D1 at the correct time is sufficient for function. 
 
Regulation of cdk4/6 by p16Ink4a
 Changes in levels of cyclin proteins are important for pushing the cell cycle forward, but just as 
important are the mechanisms that stop cell cycle progression.  At the G1-S transition, the catalytic activity of 
the cdk4/6-cyclin D complex is specifically inhibited by the cdk inhibitor p16Ink4a (50, 138).  p16Ink4a functions 
by binding to cdk4/6 opposite of the cyclin D binding site, at the catalytic cleft, distorting cdk4/6 and blocking 
the entry of ATP.  In addition, p16Ink4a also changes the shape of cdk4/6 at the cyclin D binding site, inhibiting 
cdk4/6-cyclin D complex formation (136).  Although other targets such as Rel A (12, 164) have been proposed 
for p16Ink4a, cdk4 and cdk6 remain as the only clearly validated target of p16Ink4a.  Functionally, p16Ink4a exerts 
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its growth suppressive effect through pRb, as growth suppression by p16Ink4a requires functional pRb (47, 92, 
123, 125).  In cell lines lacking functional pRb, p16Ink4a accumulates to high levels, and blocks cyclin D-cdk 
complex formation, but cannot induce growth arrest (128).  Thus, the major role of p16Ink4a is to block 
phosphorylation of pRb by inhibiting the activity of cdk4 and cdk6. 
 
p16INK4a as a tumor suppressor 
 One of the hallmarks of cancer is the loss of control of proliferation (49), therefore, it is not surprising 
that genes controlling the cell cycle are mutated in virtually all cancers.  The function of p16INK4a is to inhibit 
CDK4/6 kinase activity which leads to growth arrest, making it a likely candidate for inactivation, and human 
genetic data strongly support this theory.  Examination of p16INK4a mutations in human patients show that 
inactivating mutations of p16INK4a segregate with melanoma prone families (132). Additionally, a p16INK4a-
insensitive mutant of CDK4 (CDK4R24C) was found in a patient with melanoma, supporting the role of p16INK4a 
as the critical upstream regulator of CDK4 (163).  Mutations in p16INK4a are found at a high rate in pancreatic 
endocrine tumors (9, 117) and lung cancer (125, 139) in particular.  In lung cancer, p16INK4a mutation is only 
found in tumors with functional RB (125), and this mutually exclusive relationship between p16INK4a mutation 
and RB mutation is found in a variety of different tumor types (123).  In addition, there is increasing evidence 
that endocrine tumors such as pituitary tumors have a high frequency of epigenetic p16INK4a inactivation by 
promoter methylation (61, 122, 135, 137).  Taken together, this data strongly supports the role of p16INK4a as a 
prominent tumor suppressor in human cancer.   
 
The p53 pathway 
 The tumor suppressor gene p53 also plays a significant role in limiting cancer development.  Initial 
data suggested that p53 was a potent oncogene, as it is highly expressed in many cancer cell lines (72), and 
over-expression of p53 cooperated with Ras in transformation (31, 126), and resulted in immortalization and 
increased tumorigenicity (30, 62, 79, 102).  However it was soon recognized that p53 is mutated in many 
different cell lines, including those used to clone the p53 gene, altering the conclusions made from these 
experiments.  Subsequent studies confirmed that wild-type p53 actually suppresses transformation (29, 35) and 
mutation in p53 is required for cooperation with Ras in transformation (56, 103).  In vivo data also supports the 
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role of p53 as a tumor suppressor (118), as p53 mutations can be found in leukemia (82), osteosarcoma (96), 
lung cancer (151), colon cancer (4), and is plays a causal role in the increased cancer incidence of Li-Fraumeni 
patients (93, 145).  Expression of wild-type p53 causes a late G1 block in cells (24, 88, 173) and suppresses 
growth of tumor cells (5, 100).  In addition, loss of p53 increases tumor incidence in mice (25, 60), and over-
expression of mutant p53 leads to increased tumor formation (81).  The p53 protein functions as a 
transcriptional activator (33, 59), and many cancer derived mutants of p53 have reduced transcriptional activity 
(34, 71, 133).  A variety of stimuli can activate p53, including DNA damage (69) by ionizing radiation (76) or 
UV (94), and hyperproliferation due to Rb mutation (112, 150), and activation of p53 has been shown to induce 
p21Cip1(23, 26, 28, 51, 76), a cdk inhibitor (46, 169), which leads to cell cycle arrest.  Thus p53 functions as an 
important tumor suppressor in the majority of human cancers. 
 The levels of p53 protein are tightly controlled by its interaction with Mdm2 (53, 75, 104), an E3 
ubiquitin ligase (58).  Mdm2 binds to p53, blocks its transcriptional activity (78, 105), and shuttles it out of the 
nucleus, where it undergoes ubiquitin-mediated degradation (37, 134, 152).  The affinity of Mdm2 for p53 is 
decreased by p53 activating events, such as DNA damage-dependent phosphorylation (140, 141), allowing p53 
to activate a suite of target genes.  However, p53 also activates the Mdm2 gene (8, 67, 124, 167), generating a 
feedback loop with p53 and Mdm2 protein levels oscillating out of phase with each other (86, 156).  Loss of 
Mdm2 in mice results in embryonic lethality, due to increased levels of p53, an effect which can be rescued by 
loss of p53 (65, 107), but not downstream p53 targets such as p21Cip1 (106).  Additionally, experiments in MEFs 
have suggested that combined loss of Mdm2 and p53 is equivalent to loss of p53 alone in a variety of cellular 
properties (66, 99), suggesting that p53 is the major target of Mdm2. 
 
Regulation of the cell cycle by the Arf-p53 pathway 
 Kinase activity at the G1-S transition is also regulated by Arf, which is an alternatively spliced 
transcript of p16Ink4a.  Although p16Ink4a and Arf transcripts share identical sequence in the second and third 
exon, they each have a unique exon 1, designated 1α (p16Ink4a) or 1β (Arf) (95, 131), and are translated in 
different reading frames, thus sharing no similarity at the amino acid level.  Arf protein expression can decrease 
both cdk2 and cdk4 kinase activity in MEFs (77), and works primarily through the p53 pathway.  While Arf can 
be activated directly by E2F-1 (10), it is normally repressed during the cell cycle by the E2F3b complex, (2).  
 5
Arf functions by binding Mdm2 (68, 130, 147, 175), which leads to stabilization of p53 protein levels.  The 
exact mechanism of Mdm2 inhibition by Arf is still unclear, but has been suggested to work by blocking 
Mdm2-dependent nuclear export of p53 (175), (153).  It also may function by sequestering Mdm2 away from 
p53 (77), possibly in the nucleolus (160, 161), where it has been shown to interact with nucleophosmin/B23 
(13), causing its stabilization (20).  Regardless of the mechanism of action, Arf expression is a key factor in the 
activation of p53 in response to a variety of stimuli. 
 The decision to proliferate requires a coordinated effort of thousands of genes, using a great deal of 
energy.  Thus, it is important for the cell to be able to assess the internal and external environment, and tightly 
regulate the timing of cell division.  In the following studies, I investigate the negative control mechanisms 
which restrict cell division in conditions that are unfavorable, such as when DNA is damaged by oxidative 
stress.  In addition, I have investigated the tissue specificity and functional overlap between the various cell 
cycle inhibitors in an effort to further our understanding of how a cell makes the important decision when to, 
and importantly when not to divide. 
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CHAPTER 2 
CELLLAR SENESCENCE 
Introduction 
Senescence in human cells 
 Soon after cells were first grown in culture, it was noticed that primary lines would divide for a limited 
time, then enter an irreversible growth arrest termed senescence (34).  A major issue for proliferating cells is 
overcoming the “end replication problem” (63, 89), as every time a cell divides, it must synthesize a complete 
copy of its genome, packaged in linear chromosomes in humans.  Replication requires the binding of small 
pieces of RNA to the DNA at origins of replication, which allow the initiation of replication (55).  This creates a 
problem at the ends of chromosomes (the telomeres), as DNA is always replicated in the 5’ to 3’ direction (55).  
Thus, there comes a point at the end of a linear chromosome where there is no place for the RNA primers to 
bind, leading to the inability to copy the ends of the 3’ strand, leaving an overhang.  With each cell cycle, a 
small amount of DNA at the telomeres is not copied, leading to progressive telomere shortening.  This would be 
catastrophic for the propagation of any species, as the germline would thus be limited in its ability to divide.  
Fortunately, cells have a mechanism to deal with this issue, telomerase. 
 Telomerase is a reverse transcriptase composed of an RNA template (TR) and a catalytic subunit 
(TERT) (16, 26, 54, 62).  The telomerase holoenzyme functions by first using the RNA subunit to base-pair 
with the end few bases of the telomere DNA.  The catalytic subunit then initiates 3’ to 5’ DNA synthesis, 
elongating the 3’ overhang, and allowing the normal DNA synthesis machinery to synthesize more telomeric 
DNA.  In human cells, telomeres vary in length, ranging between 4kb and 14kb in length (18), and with each 
cell division, the telomeres lose a fraction of their length.  Somatic cells do not have active telomerase (90), 
causing telomere shortening with each division in cultured cells (2, 3, 31).  An additional problem is that linear 
ends of DNA are similar to double strand breaks in chromosomes, which are normally repaired (reviewed in 
(57)).  Thus, cells must “hide” the telomere ends, and are thought to do so by forming looped structures (T-
loops), which are highly conserved throughout evolution (13, 27, 58, 61).  Disruption of this structure through  
 
loss of protein complexes associated with T-loops or short telomeres leads to cell cycle arrest via the p53-
DNA damage pathway (17, 43, 83, 91).  But are short telomeres the reason for cellular senescence?   
 It has been noted that viral oncogenes such as HPV16-E6 (48, 87) and v-myc (21) activate 
telomerase, a clue that this is an important step in the immortalization of a cell line.  Telomere length has 
also been shown to correlate highly with the replicative capacity of human fibroblasts (4).  More direct 
experiments have shown that maintaining telomere length through stable transduction of telomerase 
extends the lifespan of some human fibroblast cell types (8, 86).  Additionally, over-expression of TRF2, a 
protein structural component of the T-loop, can protect short telomeres by maintaining structure and delays 
senescence (44).  These results point to a strong tumor-suppressive mechanism that limits replicative 
lifespan in human cells by causing growth arrest when telomeres lose their ability to form looped 
structures. 
 While telomere shortening is one mechanism of inducing senescence, very few cell types can be 
immortalized by activation of telomerase.  Many different human cell types which cannot be immortalized 
by expression of hTERT alone, require additional inactivation of p16INK4a (11, 19, 22, 29, 47, 59, 60, 69, 
71, 73).  While it has been reported that telomere shortening can induce p16INK4a (37), others have reported 
little involvement of p16INK4a, and only the induction of the p53-dependent DNA damage response (35).  
Additionally, human keratinocytes expressing hTERT, still activate p16INK4a, and senesce with kinetics 
similar to untransduced lines, and must overcome this p16INK4a barrier to immortalization (19, 71).  These 
data demonstrate that while telomeres play a role in limiting the in vitro lifespan of human cells, other 
stimuli contribute significantly to the onset of senescence through a p16INK4a-dependent pathway. 
 
Murine cellular senescence 
 In murine cells, such as MEFs, telomere shortening is largely irrelevant.  This is because the 
commonly used inbred mouse strains have telomeres that can be up to 150kb long (46), and shortening to 
lengths comparable to human telomeres requires breeding telomerase-deficient mice for 5-7 generations (5, 
7).  However, murine cells still undergo senescence, pointing to telomere-independent senescence as the 
major limitation to lifespan. A prime candidate for causing senescence in murine cells is p16Ink4a, and 
indeed, some murine cell types such as macrophages (70) and melanocytes (81) undergo p16Ink4a-mediated 
senescence.  In  MEFs, p16Ink4a is found to increase with passage (42, 65, 75, 94), yet it is paradoxically 
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unimportant in MEF senescence, and loss has no effect on lifespan (50, 78).  However, the second product 
of the Ink4a/Arf locus, Arf also increases with passage in culture (42, 75, 94).  Inactivation of either p53 
(33, 93) or Arf (42, 75) is sufficient to bypass senescence and lead to immortal cells, suggesting that the 
p53 pathway is the major determinant of cellular lifespan in MEFs. While p21CIP1 appears to be the major 
target of p53-mediated senescence in human cells (12), p21Cip1 -/- MEFs senesce with normal kinetics (67), 
suggesting that there are other relevant p53 targets in MEFs.   
 Several lines of evidence suggest that MEF senescence is induced by culture (“culture shock”) 
(80) through its influence on both Arf expression and levels of DNA damage.  For example, MEF 
senescence can be accelerated by stimuli that lead to Arf overexpression (e.g. Bmi-1 loss) (38) or increased 
DNA damage (DNA Ligase IV or Atm loss) (23, 41).  Even in embryos with deficient DNA repair (e.g. 
Atm-/- and LigIV-/-), Arf loss is sufficient for immortalization suggesting senescence requires Arf 
expression.  Additionally, senescence of MEFs has been shown to require oxidative stress produced by 
culture in 21% oxygen, as MEFs grown at 3% oxygen are immortalized and demonstrate lower levels of 
oxidative stress (68).  These data suggest that oxygen levels modulate the activation of the DNA damage 
pathway, and thus regulate entry into senescence. 
 In the following studies we wished to clarify the mechanisms of senescence in MEFs.  We have 
confirmed that genetic loss of Arf, but not p16Ink4a directly immortalizes MEFs, and show that expression of 
Arf in MEFs inversely correlates with the ability to enter S-phase.  In addition, we demonstrate that 
immortalization of MEFs at 3% O2 is due to reduced levels of Arf protein and mRNA, caused by an 
oxygen-dependent change in Arf mRNA stability.  These data point to a crucial role of Arf in mediating 
senescence in murine fibroblasts, and present a novel mechanism of oxygen-dependent regulation of the 
Ink4a/Arf locus. 
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Results 
The Arf-p53 pathway mediates senescence in MEFs   
 Genetic knock-out studies have implicated the Arf-p53 pathway in mediating senescence in MEFs.  
However, knock-out mice for p16Ink4a (78), Arf (42), or both (75) were made using different targeting 
strategies.  Notably, Arf -/- mice which retain the neomycin selection cassette at the locus (42) have altered 
expression of p16Ink4a, which may impact growth of MEFs in culture.  Mice harboring Exon 1β (Arf) and 
Exon 2 (p16Ink4a and Arf) were generated (79) using the identical targeting strategy as previously reported 
for p16Ink4a (78).  Fibroblasts from Arf -/- embryos demonstrated loss of Arf by Western blotting, but 
demonstrated normal p16Ink4a expression at early passage (Figure 1a), although p16Ink4a expression was 
increased at later passages (see P9 in Figure 1a), presumably because of the enhanced proliferation of Arf -
/- cells at these passages.  In contrast to protein levels, there was a rapid increase in both p16Ink4a and Arf 
mRNA levels during the first week in culture (Figure 1b).  Levels of p16Ink4a continued to increase during 
passage, although the rate decreased after the first 7 days, while Arf levels remained fairly stable after the 
initial increase.  However, other Ink4 genes, such as p18Ink4c and p19Ink4d showed little change upon entry 
into culture or with passage.  These data suggest that the culture environment strongly induces transcription 
of the Ink4/Arf locus.  
 In order to determine the contribution of p16Ink4a and Arf to senescence, wild-type, Arf -/-, p16Ink4a-
/-, and Ink4a/Arf-/- MEFs were assessed for lifespan.  The Arf -/- MEFs displayed identical growth kinetics 
as Ink4a/Arf-/- cells when assayed by 3T9 assay, while p16Ink4a -/- MEFs were similar to wild-type MEF 
cultures (Figure 1c). With passage, the percentage of cells in S-phase significantly decreased in wild-type 
cells, while there was no change in Arf -/- MEFs (data not shown).  In wild-type cells, nucleolar Arf 
expression increased with serial passage and was only rarely detected in BrdU+ cells (Figure 1d). Although 
this same trend was noted in p16Ink4a -/- MEFs, lines from this background more frequently harbored cells 
expressing both BrdU and Arf (6% double positive in p16Ink4a +/+ versus 13% in p16Ink4a -/-at passage 5; 
P<0.01).  This observation suggests that a minority of p16Ink4a -/- cells continued to proliferate in the setting 
of detectable Arf expression. While this small population of cells did not markedly influence growth as 
measured by a 3T9 assay (Figure 1c), this persistent proliferation may contribute to the increased 
propensity to escape of culture-induced growth arrest documented previously in p16Ink4a -/- MEFs (78).  
These results show that expression of Arf in murine cells is responsible for senescence in MEFs. 
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passage 
Figure 1:  Expression of Arf causes MEF senescence
(a) Wild-type, Arf -/-, and p16Ink4a-/- MEFs were passaged according to standard 3T9 protocols (84) and 
assessed for Arf and p16Ink4a protein at indicated passage.  Actin serves as a loading control.  (+) 
indicates positive control for Arf and p16Ink4a. 
(b) Taqman Real-Time quantitative PCR of p16Ink4a, Arf, p15Ink4b, p18Ink4c, p19Ink4d, p21Cip1, and p27Kip1 
in cultured wild-type MEFs.  Values represent fold change from E13.5 embryo which has not been 
put in culture. 18S RNA served as a loading control and normalization.  Error bars indicate +/- SEM. 
(c) 3T9 assay of wild-type, p16Ink4a-/-, Arf-/-, p16Ink4a-/-; Arf-/- MEFs. Results are the average of at least 
15 lines per genotype (68 lines total); all lines that had not senesced by passage 20 were immortal. 
(d) Immunofluorescence of wild-type MEFs at passages 5 and 11.  BrdU staining (Red, a marker of 
DNA synthesis) demonstrates a pannuclear pattern, while Arf staining in nucleolar only (Green 
punctuate dots). 
 Adapted by permission from Macmillan Publishers Ltd: [Oncogene] (79), copyright (2004)  
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Growth at low oxygen immortalizes MEFs  
 To further investigate the mechanisms that control senescence and immortalization of MEFs, we 
cultured wild-type cells in either 3% or 21% oxygen.  As reported (68), wild-type MEFs proliferated 
continuously and were immortal in 3% O2.  In contrast, MEFs grown in 21% O2 demonstrated a marked 
reduction in growth rates after ~20 population doublings consistent with senescence (Figure 2a).  Serial passage 
at 3% O2 almost completely abrogated classical features of MEF senescence: alterations of cellular morphology 
(not shown) and expression of SA-β-gal activity (Table 1).  Moreover, growth at 3% O2 obviated the 
requirement for permanent inactivation of the Arf-p53 pathway for immortalization.  Even late passage (>P20 
or more than 40 population doublings) lines grown at 3% O2 demonstrated intact Arf-p53 pathway function at 
as evidenced by the persistent ability to undergo senescence when switched to 21% O2 (Figure 2a), the ability to 
increase Arf expression upon switch from 3% O2 to 21% O2 at late passage (Figure 2b), and the retained ability 
to induce ser15-phosphorylated p53 and p53 transcriptional targets in response to UV-induced DNA damage 
(Data not shown).  These results are in accord with a previous study (68), and these data demonstrate that MEF 
senescence is abrogated by culture at 3% O2, and does not require Arf-p53 inactivation for immortalization.   
We noted that Arf-/-cells grew more rapidly than wild-type cells even at 3% O2, suggesting Arf 
function is not completely abrogated by growth at 3% O2 (Data not shown).  Consistent with this, we observed a 
low-frequency of SA-β-gal positive cells in wild-type cultures grown at 3% O2 (Table 1).  We also noted that 
upon switching from 3% O2 to 21% O2, wild-type cells reduced proliferation (Figure 2a), and increased levels 
of Arf (Figure 2b), suggesting that Arf is still functional.  Additionally, rare Arf-expressing cells detectable in 
cultures grown at 3% O2, were uniformly negative for BrdU staining (data not shown), suggesting that increased 
Arf expression can inhibit the proliferation of MEFs even when cultured at 3% O2.  Therefore, the reduction in 
the frequency of senescent cells seen in cultures at 3% O2 appears to result from a decrease in the induction of 
Arf rather than a resistance to the effects of Arf.   
Expression of oncogenic Ras has been shown to cause senescence in both MEFs and human 
fibroblasts, due to increased levels of p16Ink4a (76) and Arf (66).  However, the ability of oncogenic Ras to cause 
senescence in  human fibroblasts is reduced at low oxygen (53), as Ras has been shown to signal through the 
production of oxygen radicals (36).  We sought to determine if MEFs grown at 3% O2 retained the ability to 
undergo senescence in response to activated Ras.  To assess the effects of oxygen on Ras-induced senescence in 
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Figure 2:  Senescence can be induced in MEFs grown at 3% O2  
(a) 3T3 assay (84) of wild-type MEFs passaged at ether 21% O2 or 3% O2, or grown at 3% O2 then 
switched to 21% O2 at passage 9 (Δp9) or passage 12 (Δp12).  Each curve represents the average 
of two independent lines per genotype.  
(b) Cells were grown at 3% O2 the switched from 3% O2 to 21% O2 at passage 21 (Δp21) and 
assayed at passage 24.  Whole cell lysates were blotted for either p16Ink4a or Arf.  p16Ink4a-/-; Arf-
/- MEF lysate (-) serves as a negative control.  Actin serves as a loading control. 
(c) Early passage (P2) wild-type MEFs grown at either 21% O2 or 3% O2 were trasduced with 
Empty vector (pBABE), pBABE-H-RasG12V (H-Ras), or pBABE-K-RasG12V (K-Ras), and 
selected for 4 days.  Cultures were stained for SA-β-galactosidase expression 14 days after 
transduction. 
(d) Early passage (P2) wild-type MEFs grown at either 21% O2 or 3% O2 were trasduced with 
Empty vector (pBABE), pBABE-H-RasG12V (H-Ras), or pBABE-K-RasG12V (K-Ras), and 
selected for 4 days.  Levels of Arf mRNA were assessed by Taqman Real-Time PCR 14 days 
after transduction.  Values are relative to empty vector control (pBABE).  Error bars represent +/- 
Standard Error of the Mean (SEM). 
MEFs, we transduced cells at both 21% and 3% O2 with K-rasG12V or H-RasG12V.  Fourteen days after 
transduction both K-RasG12V and H-RasG12V were able to cause senescence in both 21% and 3% O2, as indicated 
by an increase in SA-β-gal positive cells (Figure 2c, Table 1).  Ras-induced senescence was accompanied by 
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Table 1: Senescence associated-β-galactosidase staining in MEFs cultured at 21% O2 versus 3% O2
 
Genotype Arf -/- Wild-type Wild-type Wild-type Wild-type 
Vector N/A N/A pBABE K-RasG12V H-RasG12V
3% O2 N/A 5.25%a 1.4%b 16.2%b 26.8%b
21% O2 <0.5%a 39.5%a 10.2%b 37.5%b 49.3%b
a Percent S-A-b- gal positive passage 8 
b Percent S-A-b- gal positive passage 5 
increased levels of Arf mRNA at both 21% and 3% O2 (Figure 2d).  In contrast, the transformability of 
Ink4a/Arf -/- MEFs by activated Ras was markedly reduced by growth at 3% O2, despite comparable 
transfection efficiency.  This effect was not rescued by activation of AKT (i.e. co-transfection with p110-
CAAX), and was only partially rescued by co-transfection with c-Myc or SV40 Large TAg (Data not shown).  
These results indicate that Arf is both functional and capable of inducing senescence at 3% O2 in response to 
signals such as oncogenic Ras.  However, transformation by oncogenic Ras requires an Arf-independent, 
oxygen-dependent signal. 
 
Both p16Ink4a and Arf mRNA levels are reduced at 3% oxygen.   
 To understand the basis of the Arf-dependent, anti-proliferative signal conveyed by growth at 21% O2, 
we measured the expression of Arf and related proteins with serial passage at 21% and 3% O2.  As expected, 
wild-type cells grown at 21% O2 demonstrated a marked increase in the protein expression of Arf.  However, 
cells grown at 3% O2 demonstrated lower levels of Arf protein at all passages (Figure 3a).  Levels of p21Cip1 
were also reduced at 3% O2, suggesting that the reduction in Arf protein reduces p53 dependent induction of 
downstream target genes (Figure 3a).  To determine if this effect was due to protein stability, late passage MEFs 
were treated with cyclohexamide to block protein synthesis, and protein degradation rate was assessed.  
Stability of Arf was similar at both 3% and 21% O2, suggesting that oxygen does not affect Arf levels through 
regulation of protein degradation (Data not shown).  Interestingly, protein levels of p16Ink4a behaved in a similar 
manner to Arf (Figure 3a) suggesting that oxygen may regulate the Ink4a/Arf locus at the mRNA level.  We 
investigated mRNA levels of both p16Ink4a and Arf by Taqman Quantitative Real-Time PCR to determine if 
there were differences between 3% and 21% O2. Levels of p16Ink4a and Arf were approximately 2-fold higher in 
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Figure 3:  Oxygen regulates mRNA stability of p16Ink4a and Arf 
(a) Protein expression of wild-type MEFs serially passaged at 21% O2 or 3% O2 
(b) Ratio of mRNA expression of indicated gene at 21% O2 to 3% O2.  Error bars represent +/- SEM. 
(c) Rate of decay of Arf mRNA at 21% O2 or 3% O2.  Samples are reported as ratio compared to 
untreated sample at time 0.  Lines represent best-fit exponential decay curves. 
(d) Rate of decay of GFP-(p16Ink4a/Arf) 3’UTR chimeric mRNA at 21% O2 or 3% O2.  Samples are 
reported as ratio compared to untreated sample at time 0.  Lines represent best-fit exponential decay 
curves. 
MEFs at 21% O2 than those grown at 3% O2 at all passages (Figure 3b), consistent with the differences noticed 
in protein levels (Figure 3a).  In addition, p21Cip1 mRNA levels were elevated at 21% oxygen compared to 3% 
oxygen, but this was not the case for other cdk inhibitors, such as p15Ink4b, p18Ink4c, or p19Ink4d (Figure 3b), 
suggesting that this effect was specific for p16Ink4a and Arf, but not other cdk inhibitors.  These data suggest that 
oxygen modulates the mRNA levels of p16Ink4a and Arf, resulting in increased activation of the p53 pathway at 
21% O2. 
 In order to determine if the differences in mRNA levels were due to differences in rate of transcription, 
we utilized MEFs containing a GFP cassette knocked-in to the Arf locus (95).  This construct expresses GFP 
mRNA and protein from the Arf locus in response to stimuli which activate Arf transcription, but contains none 
of the 5’UTR or 3’UTR elements found Arf mRNA.  We found no difference in GFP mRNA levels between 
Arf/GFP cells cultured at 21% O2 and those cultured at 3% O2 (Figure 3b), suggesting that changes in 
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transcription rate do not account for the differences in mRNA levels.  In human fibroblasts, p16INK4a levels have 
been shown to be affected by alterations in mRNA stability (88).  We therefore investigated the rate of mRNA 
degradation of both p16Ink4a and Arf using Actinomycin D to inhibit transcription.  We found that Arf mRNA 
was more stable at 21% O2 than at 3% O2 with a half-life of 62.3 hours compared to 30.3 hours (Figure 3c).  We 
were unable to determine whether there was a difference in p16Ink4a mRNA stability, as this message changes 
minimally for over 24 hours, a time when Actinomycin D toxicity becomes limiting (Data not shown, (30)).  
These results suggest that immortalization at 3% O2 results from reduced Arf protein due to decreased message 
stability.   
 The Ink4a/Arf locus is unique in the fact that it contains two genes with a great deal of shared DNA 
sequence, yet p16Ink4a and Arf share no amino acid similarity due to splicing into an alternate reading frame.  
Despite their unique protein structure, both p16Ink4a and Arf transcripts share a common 3’UTR, a region known 
regulate stability of the mRNA of a variety of different genes (reviewed in (6)).  In order to determine if the 
3’UTR of p16Ink4a and Arf affects message stability, we cloned the (p16Ink4a/Arf) 3’UTR onto a GFP reporter 
cassette.  This construct was transduced into Ink4a/Arf -/- MEFs, which were grown at either 21% or 3% O2, 
and levels of the GFP-(p16Ink4a/Arf) 3’UTR transcript were increased at 21% O2 compared to 3% O2 (Figure 
3b).  Taqman Quantitative Real-Time PCR was used to assess mRNA stability of the GFP-(p16Ink4a/Arf) 3’UTR 
transcript after treatment with Actinomycin D.  While there was no difference in the degradation rate of the 
Arf/GFP mRNA (data not shown), there was a decreased rate of mRNA decay at 21% O2 (t1/2 = 157 minutes) 
versus 3% O2 (t1/2 = 93 minutes) in the GFP-(p16Ink4a/Arf) 3’UTR (Figure 3d), suggesting that the 3’UTR of 
p16Ink4a/Arf regulates mRNA stability in response to changes in oxygen. 
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Discussion 
The Arf-p53 pathway in MEF senescence 
 Human and murine cells senesce when grown in culture, but the dominant mechanism of growth arrest 
appears to be different.  In many human (1, 10, 11, 19, 22, 47, 69, 71, 73) and some murine (70, 81) cell types, 
expression of p16INK4a serves as a strong telomere-independent block to immortalization.  In MEFs, while 
p16Ink4a increases with passage and reaches high levels at senescence, p16Ink4a-/- MEFs are not directly 
immortalized ((50, 78), Figure 1c) suggesting p16Ink4a does not cause senescence in MEFs.  Instead, the p53 
pathway plays a predominant role in MEF senescence, as indicated by the direct immortalization through loss of 
both p16Ink4a and Arf, Arf alone (42, 75), Figure 1c), or loss of p53 (33, 40, 85).  Additionally, the strong 
negative correlation between Arf expression and BrdU incorporation (Figure 1d), suggests that high levels of 
Arf are required for senescence in MEFs.  These apparent discrepancies may be explained by recent work 
investigating the role of polycomb group proteins in the regulation of the Ink4a/Arf locus.  Polycomb group 
genes such as Bmi-1 (38) and Cbx-7 (24) have been shown in murine cells to repress the Ink4a/Arf locus, 
presumably by modification of the global chromatin structure (reviewed in (25)).  Bmi-1, in particular, has 
recently been shown to bind directly and repress transcription of p16INK4a in human fibroblasts (9, 49), but 
strong repression of Arf appears limited to MEFs (9).  Importantly, this repression is passage-dependent, as late 
passage cells have less Bmi-1 bound to the INK4a/ARF locus than early passage cells.  The coordinate increase 
in mRNA levels of p15Ink4b, p16Ink4a and Arf in early passage MEFs (Figure 1b) is consistent with this model, 
and these results suggest that the relative importance of the p16Ink4a and p53-Arf pathways in growth arrest in 
MEFs is a cell-type specific characteristic, which may be determined by polycomb-dependent regulation of the 
Ink4a/Arf locus. 
 
Regulation of mRNA stability by oxygen 
 It was proposed over half a century ago that increased production of oxygen radicals in the human 
body could be the cause of aging (32).  The phenomenon of cellular senescence (34) was thought to model the 
condition of aging in a culture dish, and links between oxygen and senescence have long been sought.  In 
support of this theory, it has been found that senescing human fibroblasts have elevated levels of ROS (45, 82), 
and artificially increasing the levels of ROS in young fibroblasts is sufficient to induce senescence (14).  
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Conversely, senescence can be delayed in human fibroblasts (15, 64, 72), and even abolished in MEFs (68) by 
culture at low ambient oxygen, which decreases the levels of ROS.  Despite these correlations, the mechanism 
of inducing senescence by ROS has been somewhat unclear.  It has been proposed that growth of MEFs at 3% 
oxygen reduces DNA damage and subsequent p53 activation, allowing for continued proliferation (56, 68), but 
this is clearly not the entire story, as Arf-/- MEFs with intact p53 are immortalized, even at 21% O2.  We have 
shown that MEFs grown at 3% O2 have reduced levels of Arf protein and mRNA which allows for continued 
proliferation.  When grown at 3% O2, Arf is still functional and capable of inducing senescence, as moving cells 
from 3% to 21% O2 causes induction of Arf and senescence.  In contrast to human fibroblasts (53), senescence 
can be induced in MEFs at 3% O2 by transduction with oncogenic H-Ras or K-Ras, which leads to an increase 
in Arf expression.  In addition, cultures at 3% O2 have a minority of cells that have detectable Arf protein by 
immunostaining, and these cells are uniformly BrdU negative.  These data suggest that senescence requires a 
p53 activating signal such as oxygen-dependent DNA damage (68), but also requires sufficient accumulation of 
Arf to inhibit MDM2 and stabilize p53, allowing for activation of target genes. 
 Our data demonstrate a unique mechanism of regulation of the Ink4a/Arf locus, through oxygen-
dependent changes in Ink4a/Arf mRNA stability.  Recent work using GFP reporter constructs demonstrated that 
elements in the 3’UTR of the human p16INK4a transcript affect mRNA stability (88), suggesting a new 
mechanism of p16Ink4a regulation.  Due to the unique structure of the Ink4a/Arf locus, the 3’UTR sequence is 
shared between p16Ink4a and Arf, suggesting the possibility of coordinate regulation of mRNA levels.  We have 
seen that both p16Ink4a and Arf protein and mRNA are affected by oxygen (Figure 3a, b), supporting a common 
mechanism of mRNA regulation.  While it is clear that there are differences in stability of Arf mRNA between 
3% O2 and 21% O2 (Figure 3c) we were not able to measure differences in p16Ink4a mRNA due its long half-life 
and dose-limiting toxicity of Actinomycin D ((30) , data not shown).  Using a GFP reporter construct containing 
shared sequence from the murine Ink4a/Arf 3’UTR, we have demonstrated that this sequence controls mRNA 
stability in response to varying oxygen levels.  A variety of mRNA binding proteins have been shown to 
regulate mRNA stability through the 3’UTR, and two in particular are of interest.  AUF1 has been shown to 
bind to a variety of mRNAs and increased binding leads to decreased stability of the target mRNA (reviewed in 
(28)).  Levels of AUF1 have been shown to decrease at senescence, concurrent with decreased binding to the 
human p16INK4a 3’UTR, leading to increased p16INK4a stability at senescence (88).  This increase in p16INK4a 
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stability occurs at a time when ROS levels are greatly increased in human fibroblasts (82), and it is tempting to 
speculate that increased ROS may decrease AUF1, although this has not been examined thus far.  While we 
have not noted any difference in mRNA stability with passage, it has been noted that MEFs do not exhibit the 
same increase in ROS at senescence as human fibroblasts (82). Another intriguing candidate is nucleolin, which 
binds to the 3”UTR in a variety of genes such as β-globin (39), Bcl-2 (74), and gadd45α  (92), and causes 
stabilization of the 3’UTR.  In this case, there is an established link to oxygen-dependent regulation of mRNA, 
as nucleolin modulates the stability of gadd45α mRNA in response to ROS levels (92).  Intriguingly, the shared 
region of the p16Ink4a/Arf 3’UTR contains putative binding sites for both AUF1 and nucleolin, suggesting that 
either or both proteins may contribute to the regulation of p16Ink4a/Arf mRNA stability.  In summary, these data 
demonstrate a novel means of controlling expression from the Ink4a/Arf locus through oxygen-dependent 
regulation of mRNA stability. 
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Materials and Methods 
Cell Culture   
 Murine Embryo Fibroblasts (MEFs) were cultured from whole 13.5 day old embryos as described (78) 
and grown in either 21%O2 or 3%O2.  Cumulative population doublings were calculated as log2 (number of cells 
at harvest/number of cells plated) (19).  Transformations with H-RasG12V and SV-40 TAg were performed as 
previously described (77) with duplicate samples from 4-6 lines of each genotype.  Transductions with H-
RasG12V or K-RasG12V were performed as previously described (76).  Briefly, cells were selected with 1μg/ml 
Puromycin for 4 days, then harvested or fixed 14 days post-transduction.  Cells were stained SA-β-
galactosidase as previously described (20).  For cell counting of BrdU and Arf stained cells, 4600 cells per 
genotype (wild-type vs. p16Ink4a-/-) were counted from three matched pairs of independent littermate cultures at 
passage 5–11 and compared with a two-sided Fisher’s exact test.  
 
RNA preparation, qRT-PCR, and RNA stability   
 RNA isolation, reverse transcription and TaqMan Real-time PCR were performed as described 
elsewhere (52)  with the exception that reverse transcription was performed using random hexamer rather than 
oligo-dT primer and more sensitive primer/probe sets specific for p16Ink4a and Arf were used (51).  18S rRNA 
was used as a loading control for all reactions.  Two independent Probe/primer sets for GFP were constructed: 
Probe (CCACCCTCGTGACCACCCTGAC), Left primer GFPF (CTGCACCACCGGCAAGCT), Right Primer 
GFPR (GGGTAGCGGCTGAAGCACTG) and Probe (CCACCCTCGTGACCACCCTGAC), Left Primer 
GFPF2 (CCACCTACGGCAAGCTGAC), Right primer GFPR2 (AAGTCGTGCTGCTTCATGTG).  Primer 
sets for 18S (Hs99999901_s1), p15Ink4b (Mm00483241_m1), p18Ink4c (Mm00483243_m1), p19Ink4d 
(Mm00486943_m1), p21Cip1 (Mm00432448_m1), and p27Kip1 (Mm00438167_g1) were purchased from Applied 
Biosystems.  To assess RNA stability, MEFs were treated for up to 24 hours with 1μg/ml Actinomycin D to 
block transcription.  Rate of decay was measured by Taqman Real-Time PCR for gene of interest at various 
treatment times, and compared to untreated MEFs. 
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GFP-(p16Ink4a/Arf)-3’UTR reporter plasmid  
 To construct the GFP (p16Ink4a/Arf) 3’UTR reporter plasmid, a fragment corresponding to the 3’UTR of 
the p16Ink4a gene was PCR amplified from genomic DNA with primer set:  
Left (GCATGGACGAGCTGTACAAGTAAATCCGGCCTCAGCCCGCCTTTTTCTTCTTAGC),  
Right (CGCGGAATTCGGATGGGGAACCAGAGTACA).   
The coding sequence of enhanced green fluorescent protein (GFP) was PCR amplified from pEGFP-1 
(Clonetech) using the primer set:  
Left (ATATGGATCCGAAAGCGAACTCGAGGAGAG),  
Right (AGGAGAGCCATCTGGAGCAGCATGGTGAGCAAGGGCGAGGAGCTGTTCA).   
The GFP coding sequence and (p16Ink4a/Arf) 3’UTR sequences were joined and PCR amplified using primer set:  
Left (AGGAGAGCCATCTGGAGCAGCATGGTGAGCAAGGGCGAGGAGCTGTTCAC),  
Right (CGCGGAATTCGGATGGGGAACCAGAGTACA).   
The resulting fragment was cloned into pBABE-puro plasmid using EcoRI and BamHI restriction digest. 
 
Western blotting   
 Western blot assays were performed as described (79).  Briefly, cells were lysed in RIPA buffer 
(200mM Tris-HCl pH 7.4, 100mM NaCl, 10% glycerol, 0.5% SDS, 1% Triton X-100, Roche complete Mini-
tabs -1 tablet/ 10ml, Calbiochem Phosphatase inhibitor cocktail set I and II -1:100) for 30 minutes at 4oC, 
centrifuged for 10 minutes at 13 x g, supernatant was kept, and total protein was determined by colorimetric 
assay (Bio-Rad).  Protein was loaded onto 4-12% or 10% Bis-Tris NuPAGE mini-gels (Invitrogen) and run in 
NuPAGE MES running buffer (Invitrogen).  Protein was transferred onto PDVF membranes (Millipore) and 
probed with antibodies against p16Ink4a (M-156, Santa Cruz), p19Arf (Ab-80, Abcam), Actin (C-1, Santa Cruz).  
Protein levels were visualized using Enhanced ECL reagent (Amersham).   
 
Immunofluorescence   
 Immunofluorescence was done as described previously (71) with some modifications. Briefly, cells 
were BrdU pulsed for 24 h and fixed in 4% paraformaldehyde at indicated passages, incubated in 0.1% Triton 
X-100, then treated for 1 h with 0.2 N HCl, and neutralized with 0.1M sodium borate buffer. Cells were stained 
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using antibodies to BrdU (Roche) and Arf (Ab80, Abcam) for 1 h. Proteins were visualized by using 
AlexaFluor562 and 488 Molecular Probes secondary antibodies. 
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 CHAPTER 3 
THE ROLE OF p16Ink4a AND p18Ink4c IN THE REGULATION OF cdk4/6 
Introduction 
The Ink4 family of cyclin-dependent kinase inhibitors 
The Ink4 family of proteins consists of four members, p16Ink4a (63, 71, 89), p15Ink4b (27, 63), p18Ink4c 
(22, 29), and p19Ink4d (23, 29), and all are specific inhibitors of cdk4/6-cyclin D complexes.  Both p16Ink4a and 
p15Ink4b consist of four ankyrin repeats, with ~ 80% sequence similarity to each other, while p18Ink4c and p19Ink4d 
have a fifth ankryin repeat (reviewed in (66)) which has been suggested, in the case of p18Ink4c to increase 
stability (25, 47).  All four inhibit cdk4 and cdk6 by binding opposite the cyclin binding site, causing an 
allosteric shift, blocking cyclin binding and ATP hydrolysis (5, 8, 24, 34, 46, 47, 68, 90).  While all four Ink4’s 
appear to bind cdk4 and cdk6 with comparable affinity (84), there have been some reported differences in the 
regulation of different Ink4’s.  For example, p18Ink4c has been shown to have one site of phosphorylation, while 
p19Ink4d has multiple phosphorylation sites (84).  Conflicting results have been reported for p16Ink4a, with one 
group finding no phosphorylation (84) and the other finding multiple phosphorylation sites (24).  While p15Ink4b, 
p16Ink4a, and p18Ink4c have similar protein stability of more than 8 hours (59, 69, 73), p19Ink4d is unstable, with a 
half-life of ~30 minutes, due to ubiquitination (83).  In addition, p19Ink4d protein levels fluctuate with the cell 
cycle, with expression peaking during S-phase (29, 83).  It general, however, the functional relevance of these 
biochemical distinctions between the Ink4 family members remains unclear. 
 Despite the biochemical similarities, mice lacking individual Ink4 genes exhibit different phenotypes.  
Mice lacking p19Ink4d mice are overtly normal, but have testicular atrophy and deafness (10, 94).  Mice lacking 
p15Ink4b demonstrate increased proliferation in the lymphoid lineages, and a low incidence of spontaneous tumor 
formation (44).  On the other hand, mice lacking p16Ink4a develop lymphomas and sarcomas (39, 75, 76), while 
p18Ink4c -/- mice develop pituitary tumors of the intermediate lobe (16, 44).  Both p16Ink4a -/- (39, 75, 76) and  
 
 
p18Ink4c -/- (4) mice exhibit increased susceptibility to spontaneous and carcinogen-induced tumors, but with 
minimal overlap of tumor spectrum.  These phenotypic differences among the Ink4-deicient strains are thought 
to reflect different patterns of expression in vivo, although subtle biochemical differences in the Ink4 proteins as 
described above cannot be ruled out as a reason for these differences. 
  
The Cip/Kip family of cyclin-dependent kinase inhibitors 
In contrast to the narrow spectrum cdk inhibitors of the Ink4 family, cdk activity can also be regulated 
by the Cip/Kip family proteins, which consists of three members, p21Cip1 (15, 28, 88), p27Kip1 (62), and p57Kip2 
(45).  These proteins all have the ability to bind in trimeric complexes (67) to a variety of cyclin-cdk pairs.  
Cip/Kip proteins are potent inhibitors of cdk2 activity (9, 52, 62, 80, 88), but their role in the regulation of 
cdk4/6- cyclin D is less clear.  On the one hand, data indicate that p21Cip1 and p27Kip1 promote assembly of 
cdk4/6-cyclin D complexes and therefore increase cdk4/6-associated activity (11, 43, 60).  On the other hand, it 
has been suggested that active cdk4/6-cyclin D complexes can form in the absence of p21Cip1 and p27Kip1 (3, 
81), and that p21Cip1/p27Kip1 are direct inhibitors of cdk4 and cdk6 (3, 62, 88).  Importantly, germline p27Kip1 
deficiency in vivo can rescue phenotypes associated with cyclin D1 loss (19), and enhance phenotypes 
associated with cdk4 activation (16, 79), suggesting that the Cip/Kip family and Ink4 family interact 
genetically.  In contrast, cdk2 loss does not rescue tumorigenesis associated with p27Kip1 loss (2, 51), suggesting 
interaction with cdk2 is not required for the anti-proliferative effects of Cip/Kip proteins in tissues such as the 
pituitary. 
 Elucidation of the control of the proliferative cdk’s by the partially redundant cdki’s remains a major 
hurdle in the clear understanding of the cell cycle, a problem made more difficult by the compensation seen 
among family members.  In this study we have investigated the effects of combined loss of p16Ink4a and p18Ink4c 
in vitro and in vivo.  We show that the loss of one Ink4 family member, such as p18Ink4c, results in compensatory 
increases in other members such as p16Ink4a both in MEFs and in vivo.  Using genetic and pharmacologic 
approaches, we show that specific in vivo tissues are dependent on cdk4/6 for proliferation.  In these tissues, as 
is seen in MEFs, p16Ink4a partially compensates for p18Ink4c deficiency to restrain proliferation and the malignant 
behavior of p18Ink4c-deficient tumors.  These data suggest that p16Ink4a and p18Ink4c function to regulate 
physiologic and aberrant proliferation in specific tissues of adult mice. 
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Results 
Loss of both p16Ink4a and p18Ink4c in MEFs increases cdk4 activity   
 Expression of p16Ink4a has been associated with senescence in human cells (1, 13, 36, 70), but appears 
to play little role in the regulation of MEF senescence (39, 75).  In an effort to determine the effects of cdk4/6 
activity on proliferation in MEFs, 
we generated mice lacking both 
p16Ink4a and p18Ink4c.  Cultured 
wild-type MEFs demonstrate 
significant expression of p16Ink4a 
that markedly increases with serial 
passage (58, 93), yet p16Ink4a-
deficient MEFs enter senescence 
with identical kinetics as wild-type 
cells (39, 75).  MEFs lacking 
p18Ink4c (44), p19Ink4d (94), or both 
(92) also show no differences in 
lifespan despite significant 
expression of these proteins in 
cultured MEFs ((93), and data not 
shown).  In contrast, p15Ink4b -/- 
MEFs demonstrate a modest 
extension of lifespan (44), and 
cells carrying the Ink4-insensitive 
cdkR24C mutation are immortal in 
culture (64, 78).  Serial passage of 
p16Ink4a -/-; p18Ink4c -/- MEFs 
revealed identical proliferation a
lifespan as wild-type MEFs 
(Figure 4a), and these cells entered senescence with identical kinetics as wild-type cells.  Additionally, p16
nd 
Ink4a -
Figure 4:  MEFs from p16Ink4a -/-; p18Ink4c-/- mice show enhanced 
cdk4 kinase activity  
(a) 3T9 assay of wild-type (WT) and p16Ink4a-/-; p18Ink4c-/- (DKO) 
MEFs. Error bars indicate +/- SEM.   
(b) Levels of cyclin E, cdk2, cyclin D1, cdk4, and p16Ink4a, in 
asynchronously growing wild-type (WT) and p16Ink4a-/-; 
p18Ink4c-/- (DKO) MEFs of indicated passage.  Actin serves as a 
loading control. 
(c) In vitro cdk4 (left) and cdk2 (right) kinase activity of wild-type 
MEFs with passage (top). Cdk4 or cdk2 complexes were 
immunoprecipitated from MEFs of indicated passage and 
kinase activity was assessed against GST-Rb-769 substrate.  
“NP” denotes no primary antibody. “NS” indicates no GST-
pRb substrate.  1/6th of the total cdk4 or cdk2 
immunoprecipitated is shown as loading control (bottom). 
(d) In vitro cdk4 kinase activity of wild-type (WT) MEFs (left) or 
p16Ink4a-/-; p18Ink4c-/- (DKO) with passage.  
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/-; p18Ink4c -/- MEFs demonstrated similar cdk and cyclin D1 expression (Figure 4b) with serial passage.  In an 
effort to understand the underlying mechanisms driving MEF proliferation, we assessed the kinase activity of 
cdk4 and cdk2 with serial passage.  As reported for human fibroblasts (14, 49), cdk2 kinase activity decreased 
with passage, correlating highly with the onset of senescence (Figure 4c).  In contrast to reports in human cells 
(70), cdk4 activity actually increased with passage, with its highest level of activity when cells were entering 
senescence (Figure 4c).  Cyclin D protein and mRNA levels were increased at late passage in MEFs (Figure 4b, 
data not shown), as has also been reported for human fibroblasts (14, 49).   p16Ink4a -/-; p18Ink4c-/- MEFs 
demonstrated slightly increased cdk4 kinase activity compared to wild-type cells at all passages (Figure 4d), 
although there was little effect on proliferative lifespan (Figure 4a).  These data show that p16Ink4a and p18Ink4c 
regulate cdk4 kinase activity in MEFs, but that increased cdk4 activity does not result in an increase of 
proliferation in these cells, which appears to be predominantly determined by cdk2 kinase activity.  
 
Loss of p16Ink4a and p18Ink4c decreases density-dependent arrest, but does not contribute to 
transformation   
 Growth arrest at high density in MEFs is partially mediated by p16Ink4a (74), but a role for p18Ink4c has 
not been explored.  We assessed the ability of p18Ink4c to cooperate with p16Ink4a loss in the regulation of high 
density growth.  Plates were re-fed but not passaged for 21 days, then assessed for cell number.   Compared to 
wild-type cells, p16Ink4a -/-; p18Ink4c -/- MEFs demonstrated a 45% increase in cell number (p=0.011) (data not 
shown), similar to the effect seen with loss of p16Ink4a alone (74).  As has been previously reported for p16Ink4a -
/- (74, 75) and p18Ink4c -/- (44) MEFs, transformation by H-rasV12G alone or H-RasV12G + SV40 T-Ag was not 
significantly different between wild-type, p16Ink4a -/-, p18Ink4c -/- or p16Ink4a -/-; p18Ink4c -/- MEFs(data not 
shown).  These data confirm an effect of p16Ink4a on density arrest in MEFs, but suggest only at most a modest 
role for p16Ink4a and p18Ink4c in resisting Ras-mediated transformation in MEFs. 
 
p16Ink4a -/-; p18Ink4c -/- mice develop aggressive pituitary tumors   
 To analyze the effects of combined p16Ink4a and p18Ink4c deficiency in vivo, we compared mice lacking 
p16Ink4a and/or p18Ink4c.  Both p16Ink4a and p18Ink4c lie on the murine chromosome 4 (91) requiring a modified 
breeding scheme similar to that reported for mice lacking p15Ink4b and p18Ink4c (44).  p16Ink4a -/-; p18Ink4c -/- mice 
were produced in the expected ratio based on calculated frequency of recombination between p16Ink4a and 
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p18Ink4c, were fertile, and exhibited normal behavior.  No significant difference in body weight was found 
between p16Ink4a-/-; p18Ink4c-/- and wild-type or p16Ink4a+/-; p18Ink4c+/- mice in their mixed genetic background.  
With aging, p16Ink4a-/-; p18Ink4c-/-  mice demonstrated increased morbidity with a median tumor-free survival of 
42.7 weeks, compared to 
68.8 weeks for p18Ink4c-/-  
mice (p<0.001) and  greater 
than 70 weeks for p16Ink4a -
/- mice (p=0.005) (Figure 
5a), demonstrating strong 
cooperation between loss of 
p16Ink4a and p18Ink4c in 
promoting tumorigenesis.   
 Morbidity was 
associated with large 
pituitary tumors of the 
intermediate lobe, in some 
cases producing non-
communicating 
hydrocephalus, hind limb 
paralysis and/or pontine 
compression (Figure 5b).  
While pituitary tumors were 
found in all p16Ink4a-/-; 
p18Ink4c-/- mice examined 
over 30 weeks of age, 
p18Ink4c-/- mice developed 
pituitary tumors as previously reported (16, 44) with ~ 50% penetrance by 1 year.  No pituitary tumors were 
found in p16Ink4a-/- mice at any age examined.   p16Ink4a -/-; p18Ink4c-/- mice developed non-pituitary tumors (e.g. 
sarcomas) at a comparable frequency to that of p16Ink4a-/- mice (data not shown) suggesting that cooperation 
Figure 5:  Mice lacking p16Ink4a and p18Ink4c develop pituitary tumors
(a) Tumor-free survival of mice lacking p16Ink4a and/or p18Ink4c. The control 
groups consisted of p16Ink4a+/+; p18Ink4c-/- (n=14) or p16Ink4a-/; -
p18Ink4c+/+ (n=10) and were compared to the p16Ink4a-/-; p18Ink4c-/- (n=27) 
group. Mean survival for p16Ink4a-/-; p18Ink4c-/- mice is 42.7 weeks, 
p18Ink4c-/- mice is 68.8 weeks, and p16Ink4a-/- mice is >70 weeks.     
(b) MRI of wild-type (WT, left) and p16Ink4a-/-; p18Ink4c-/- (DKO, right) mice at 
44 weeks of age.  T1-weighted images (top) are at the level of the 
pituitary, which is indicated by the white arrow.  T2-weighted images 
(bottom) are taken at the level of the ventricles. Note marked 
hydrocephalus (black arrow) in the mouse on right.  
(c) Representative gross samples and H&E staining of pituitaries of indicated 
genotypes at 35 weeks of age.  Pituitary in gross samples is outlined 
(dashed line). 
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between p16Ink4a and p18Ink4c in tumor suppression was most marked in the pituitary.  While this observation is 
in accord with previous findings showing an important anti-cancer role of cdk4/6 regulation in tumorigenesis of 
the intermediate pituitary (16, 64), loss of p18Ink4c combined with loss of p15Ink4b (44)  or p19Ink4d (92) , did not 
appreciably accelerate pituitary formation nor increase incidence, suggesting that p16Ink4a plays a predominant 
role in the prevention of pituitary tumorigenesis in p18Ink4c -/- mice.   
In an effort to understand the basis of this cooperation, we performed gross, histologic and molecular 
analysis of age-matched wild-type, p16Ink4a-/-, p18Ik4c-/-, and p16Ink4a-/-; p18Ink4c-/- mice.  Inspection of 
pituitaries of 35 week old mice revealed normal macroscopic and microscopic structure in wild-type and p16Ink4a 
-/- mice (Figure 5c).  Consistent with previous data (16), p18Ink4c-/- mice at this age showed hyperplasia of the 
intermediate lobe with modest associated disruption of the gland architecture.  However, p16Ink4a-/; -p18Ink4c-/- 
mice demonstrated a marked increase in the size of the pituitary and anatomic disarray of the intermediate lobe 
with near complete effacement of the posterior lobe (Figure 5c).  Similar to cdk4R24C knock-in mice (64), cystic 
degeneration, hemorrhage and necrosis were commonly seen in the pituitaries of p16Ink4a-/-; p18Ink4c-/- mice, 
even in animals less than 20 weeks of age, but were rarely seen in p18Ink4c -/- mice.  Pituitary tumors in p16Ink4a-
/-; p18Ink4c-/-  mice stained strongly for adrenocortotrophic hormone (ACTH), but not other peptide hormones 
(LH, FSH, GH or prolactin) made in the pituitary, suggesting tumors were of the adrenocorticotroph lineage.  
Additionally, blood serum levels of α-MSH increased with age in p16Ink4a-/-; p18Ink4c-/- mice (data not shown), 
as was reported for Rb+/- mice (30).  These data suggest that p16Ink4a serves to limit tumor progression in the 
intermediate pituitary of p18Ink4c -/- mice. 
 
p16Ink4a functionally compensates for p18Ink4c loss in the pituitary   
 To determine the functional consequences of combined p16Ink4a and p18Ink4c loss, we determined the 
Ki67 proliferative index in the intermediate lobe of the pituitary in adult mice.  The intermediate lobes of the 
pituitary in 35 week old wild-type, p16Ink4a -/-, p18Ink4c -/-, and p16Ink4a -/-; p18Ink4c -/- mice were compared.  The 
rate of proliferation was comparable in wild-type (0.4%) and p16Ink4a -/- (0.5%) mice, but significantly increased 
in p18Ink4c -/- mice (1.9%, p<0.05 for both pair-wise comparisons).  Mice lacking both p16Ink4a and p18Ink4c 
demonstrated an even greater increase in proliferation (2.7%) above wild-type (p=0.003), p16Ink4a -/- (p<0.001), 
and p18Ink4c -/- mice (p=0.09) (Figure 6a).  This result suggests that the increase in p16Ink4a expression partially 
compensates for p18Ink4c loss in the intermediate pituitary, even in animals of intermediate (35 week old) age. 
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 To understand the mechanistic basis for this cooperation in tumors, we performed an analysis of cdk-
inhibitor (CDKI) expression in the pituitary of wild-type and p18Ink4c-/- mice.  While there was a modest 
increase in Arf (3.4 fold), p21Cip1 (2.3 fold), p15Ink4b (2.4 fold), and p19Ink4d (1.5 fold) mRNA in p18Ink4c-/- mice 
when compared to wild-type mice, expression of p16Ink4a mRNA was by far the most increased (18.2 fold) in the 
pituitary of young 
(10.6 week old) 
p18Ink4c-/- mice 
(Figure 6b).  
Consistent with 
previous findings 
(20), p18Ink4c-/- mice 
of this age exhibited 
only mild hyperplasia 
with no evidence of 
tumors and had 
overtly normal tissue 
architecture (data not 
shown).  Although 
this analysis does not 
exclude an impact of 
p18Ink4c-deficiency on 
the protein expression 
of other cell cycle 
regulators such as 
p27Kip1 (16), it 
suggests a potent in 
vivo mechanism of 
compensation for 
germline p18Ink4c 
Figure 6: Loss of p16INK4a and/or p18INK4c affects proliferation in the pituitary  
(a) Quantification of proliferative index in the pituitary of 35 week old wild-type 
(WT), p16Ink4a-/-, p18Ink4c-/-, and p16Ink4a-/-; p18Ink4c-/- (DKO) mice. At least 2 
mice per genotype were used, and all cells in the intermediate lobe were counted 
for each pituitary.  Error bars indicate +/- SEM. 
(b) Relative mRNA expression by real-time PCR of indicated tissue from 10.6 week 
old wild-type (WT) and p18Ink4c-/- mice.  Values represent the ratio of expression 
of indicated gene in p18Ink4c-/- mice compared to wild-type littermates.  At least 
2-6 mice per genotype were assayed, samples measured in triplicate.  18S RNA 
served as a loading control and normalization.  Error bars indicate +/- SEM. 
(c) Relative increase in mRNA expression of p16Ink4a, Arf, p18Ink4c, p15Ink4b, p19Ink4d, 
and p21Cip1 in the pituitary with aging. Ratio of fold increase in old (54-59 
weeks) vs. young (10.6 weeks) is shown by p18INK4c genotype.  At least two mice 
per genotype were assayed, samples measured in duplicate.  Error bars indicate 
+/- SEM. 
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deficiency by increased transcription of p16Ink4a.  
 Previous studies have demonstrated that p16Ink4a expression increases with age in most mammalian 
tissues (41, 93), and we noted that total pituitary similarly exhibited an increase in p16Ink4a expression with 
aging (Figure 6c).  A comparable age-induced induction of p16Ink4a expression was noted in p18Ink4c-/- mice 
such that the ratio of p16Ink4a expression in old (~57 week old) versus young (10.6 week old) pituitary was the 
same for wild-type or p18Ink4c-/- mice (Figure 6c).  Therefore, old p18Ink4c-/- mice demonstrated a >40-fold 
increase in the mRNA expression of p16Ink4a compared to young wild-type mice, indicating the additive 
induction of p16Ink4a in this compartment in response to aging and p18Ink4c deficiency.  
 
Figure 7: Ink4 family members show transcriptional compensation in 
MEFs   
(a) Real-Time PCR of mid-lifespan (~10 population doublings) MEFs 
lacking p16Ink4a or p18Ink4c or both (DKO). Values are reported on a 
log2 scale as fold change from wild-type levels.  18S RNA served as 
a loading control and normalization.  Error bars indicate +/- SEM. 
(b) Western blot analysis of mid-lifespan (~10 population doublings) 
MEFs lacking p16Ink4a or p18Ink4c or both (DKO).  Actin serves as a 
loading control.  Arrow indicates specific band in Arf blot. 
(c) In vitro cdk4 kinase activity of wild-type (WT), p16Ink4a-/-, p18Ink4c-
/-, and p16Ink4a-/-; p18Ink4c-/- (DKO) MEFs (top). Cdk4 complexes 
were immunoprecipitated from mid-lifespan (~10 population 
doublings) MEFs.  Kinase activity was assessed against GST-Rb-
769 substrate.  “NP” denotes no primary antibody. “NS” indicates 
no Rb substrate.  One-sixth total cdk4 immunoprecipitated is shown 
as loading control (bottom).  Relative activity represents fold 
difference from wild-type. 
 
Ink4 family members can 
transcriptionally compensate 
for loss of other members   
 In order to determine if 
the increase in p16Ink4a mRNA in 
the pituitary was tissue-specific, 
we examined other tissues from 
p18Ink4c -/- mice.  p16Ink4a levels 
were elevated in the adrenal 
glands (32.3-fold), spleen (4.3-
fold), and kidney (3.9-fold) of 
p18Ink4c -/- mice, but there was no 
discernable change in p16Ink4a in 
the lung (Figure 6b).  The 
pituitary, adrenal glands, and 
spleen also demonstrated 
moderately elevated levels of Arf 
and p15Ink4b, but little change was 
seen in the kidney or the lung.  
These results suggest that loss of 
47 
p18Ink4c induces expression of other cdk inhibitors, specifically p16Ink4a in a tissue specific fashion in vivo. 
 It is possible that changes in cdk inhibitor levels could be a non-cell autonomous effect due increased 
in vivo proliferation from p18Ink4c loss.  We thus turned our attention to a more purified cell system, MEFs, 
which express all four Ink4 proteins (93), and examined mid-lifespan MEFs (~10 population doublings) for cdk 
inhibitor expression.  p16Ink4a -/- MEFs had a significant increase in p15Ink4b (5.5-fold), moderate increases in 
Arf (2.5-fold) and p21Cip1 (1.6-fold), and a slight increase in p19Ink4d (1.3-fold) at both the mRNA (Figure 7a) 
and protein (Figure 7b) levels when compared to wild-type MEFs.  As was seen in the various tissues in vivo 
(Figure 6b), p18Ink4c -/- MEFs demonstrated the greatest increase in p16Ink4a levels (2.9-fold), and more modest 
change in Arf (1.9-fold), p21Cip1 (1.4-fold), and p15Ink4b (2.1-fold), with little change in p19Ink4d (0.9-fold).  
MEFs lacking both p16Ink4a and p18Ink4c showed a large difference in the expression of p15Ink4b (4.8-fold), and 
smaller increases for Arf (2.8-fold), p21Cip1 (1.8-fold), and p19Ink4d (2.0-fold).  There were no detectable 
differences in p27Kip1 mRNA (data not shown) or protein (Figure 7c) between genotypes.  Interestingly, all 
changes in mRNA levels were closely mirrored by changes in protein expression, suggesting that protein and 
message correlate highly under these conditions (compare Figure 7a and Figure 7b).  Importantly, the 
compensation among the Ink4 proteins is not complete, as p16Ink4a -/-, p18Ink4c-/, and p16Ink4a-/-; p18Ink4c-/- 
MEFs demonstrate elevated cdk4 kinase activity (Figure 7c) compared to wild-type cells.  In aggregate, these 
results suggest that increased cdk4 activity due to loss of Ink4 proteins can be partially compensated for through 
activation of either p15Ink4b or p16Ink4a both in vitro and in vivo. 
 
p16Ink4a exerts age-dependent inhibition of proliferation in the islets   
 Expression of p16Ink4a had been shown to increase in a variety of murine tissues with aging (41, 93).  
Specifically, p16Ink4a has been shown by immunohistochemistry to increase with age in the pancreatic islets of 
both humans (56) and mice (41).  We wished to examine the effects of p16Ink4a expression on the islets with 
aging.  We first extracted pancreata from young (12-14 week) and old (64-80 week) mice, and isolated islets as 
previously described (55).  mRNA was made from islets and exocrine pancreas, and analyzed by Taqman Real-
Time PCR for expression levels of p16Ink4a, Arf, p15Ink4b, p18Ink4c, p19Ink4d, p21Cip1, p27Kip1, and the islet-specific 
transcript Pdx-1.  Pdx-1 was detected only at low levels in the exocrine pancreas, but enriched in the islets and 
changed little with aging.  Although undetectable in the exocrine pancreas, p16Ink4a expression increased ~14 
fold with aging in the islets, and was accompanied by a smaller increase in Arf levels (Figure 8a).  In contrast, 
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no other cdk inhibitor was increased more than 2-fold with aging in the islets (data not shown).  
 Cultured β-cells undergo senescence associated with increased p16Ink4a (26), and proliferation in the 
pancreatic β-cells decreases with age (77).  We wished to investigate whether the increase in p16Ink4a seen in 
islets with aging had an effect on 
proliferation.  We determined 
proliferation of islets in young (
week) and old (60-70 week) mice
by Ki67 staining in both wild-ty
and p16
10 
 
pe 
Ink4a-/- mice.  While 
proliferation in wild-type mice 
decreased with age, p16Ink4a-/- 
mice maintained significantly 
higher rates of proliferation at old 
age (Figure 8b).   
 To investigate whether 
over-expression of p16Ink4a 
affected islet proliferation, we 
generated a single-copy BAC 
transgenic (p16Ink4a TG).  These 
mice expressed a mean of 5-fold 
increase in p16Ink4a expression in 
all tissues examined (Data not 
shown).  Proliferation in the islets 
of p16Ink4a TG mice was 
significantly decreased (p<0.001) 
in young mice (26-32 weeks) 
compared to wild-type littermates (Figure 8c).  Both wild-type and p16Ink4a TG mice decreased proliferation 
with age (Figure 8c), however, old mice (94 weeks) were statistically indistinguishable (p=0.18).  These results 
demonstrate that p16Ink4a regulates proliferation in the pancreatic islets in an age-dependent manner. 
Figure 8: p16Ink4a limits islet proliferation in an age-dependent fashion  
(a) Expression of p16Ink4a, Arf, and Pdx-1 as determined by TaqMan on 
islets and exocrine pancreas from mice of indicated ages.  Relative 
expression is shown normalized to islet expression in young mice.  
“<” indicates expression beneath the lower limit of detection.  
(b) Percent Ki-67 positive cells of pancreatic islets from p16Ink4a+/+ and 
-/- mice of indicated ages.  Error bars indicate +/- SEM, p-values 
were determined by Mann-Whitney test. 
(c) Percent Ki-67 positive cells of pancreatic islets from p16Ink4a wild-
type (WT) and overexpressing p16Ink4a BAC transgenic (TG) mice 
of indicated ages.  Error bars indicate +/- standard error of the mean 
(SEM), p-values were determined by Mann-Whitney test. 
Adapted by permission from Macmillan Publishers Ltd: [Nature] (40), 
copyright (2006) 
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 p16Ink4a and p18Ink4c coordinately control proliferation in the islets   
 p18Ink4c has been reported to regulate islet size in a cdk4 dependent manner (61), but its expression 
does not change with aging in the islets (40, 41).  As previously reported for p18Ink4c -/- mice (61), we found that 
p16Ink4a-/-; p18Ink4c-/- mice demonstrated a modest increase in median islet size compared to wild-type and 
p16Ink4a -/- mice at 35 weeks of age (Figure 9a).  There was no discernable difference in islet size between 
p18Ink4c-/- and p16Ink4a-/-; 
p18Ink4c -/- mice in animals of 
this age.   Double staining with 
Ki67 and insulin indicated that 
the majority (>80%) of 
proliferating islet cells were β-
cells (data not shown), whose 
replication is regulated by 
cdk4, p18Ink4c and cyclin D2 in 
the adult (21, 42, 61, 65, 87).  
In mice of this age, no 
significant difference in 
proliferation was seen between 
wild-type (0.58%), p16Ink4a-/- 
(0.67%), or p18Ink4c-/- (0.71%) 
islets for any pair-wise comparison (Figure 9b).  However, p16Ink4a-/-; p18Ink4c-/- islets had a significantly higher 
rate of proliferation (0.98%) than wild-type (p=0.02), p16Ink4a-/- (p=0.08), and p18Ink4c-/- (p=0.02) islets.  It is 
important to note that these studies were carried out in young mice, and we expect the effects of p16Ink4a loss 
would be more pronounced in older mice, as p16Ink4a expression potently inhibits islet proliferation in an age-
dependent manner (Figure 8b).  In aggregate, these data suggest that p16Ink4a and p18Ink4c coordinately regulate 
cdk4/6-dependent proliferation in the pancreatic β-cells of adult mice. 
Figure 9: cdk4/6 activity regulates proliferation in the adult islet  
(a) Islet size in 35 week old p16Ink4a-/-, p18Ink4c-/-, and p16Ink4a-/-; p18Ink4c-/- 
(DKO) mice.  Data is shown as a box-whisker plot, where the box 
represents the 25th to 75th percentile of the data and the whiskers 
represent the entire range of the data.  Median is indicated by line in the 
box.  Islet size is reported in arbitrary units of are. 
(b) Quantification of proliferative index in the pancreatic islets of 35 week 
old wild-type (WT), p16Ink4a-/-, p18Ink4c-/-, and p16Ink4a-/-; p18Ink4c-/- 
(DKO) mice.  At least 2 mice per genotype and at least 42 islets per 
genotype were counted.   Error bars indicate +/- SEM. 
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Cdk4/6 kinase activity is required for proliferation in specific compartments in adult mice   
 Genetic data have suggested a role for cdk4 in the regulation of proliferation in the pituitary and the 
pancreatic islets (16, 21, 61, 65, 78).  We have found that these tissues demonstrate increased proliferation in 
mice lacking the cdk4/6 inhibitors p16Ink4a and p18Ink4c (Figure 6a, Figure 9b), suggesting a role for cdk4/6 
catalytic activity in the 
regulation of these tissues in 
adult mice.  However, c
kinase activity is required
development of certain 
embryonic tissues, leading t
late embryonic lethality in 
cyclin D (38) or cdk4/6 (50) 
null animals, thus limiting
the ability to examine adult
tissues.  To address this 
issue, we determined th
effect of acute cdk4/6 
inhibition in 26 week old 
p16
dk4/6 
 for 
o 
 
 
e 
Ink4a-/-; p18Ink4c -/- mice 
using PD 0332991, a specific 
inhibitor of cdk4/6, but not 
cdk2 or other tested kinases 
(85).  PD 0332991 is a 
pyrido[2,3-d]pyrimidin-7-
one compound modified with a 2-aminopyridine side chain that has been shown to block the growth of pRB-
competent human cell lines and xenografted tumors with potent activity at nanomolar concentrations.  PD 
0332991 demonstrates good oral bioavailability, can be given to mice for prolonged treatment with minimal 
toxicity (18, 85).  Comparable to its potency in human cells, PD 0332991 was shown to inhibit murine cdk4 
activity at doses as low as 50nM, whereas cdk2 activity was not affected even at micromolar concentrations 
Figure 10:  Inhibition of cdk4/6 blocks proliferation in some, but not all 
tissues 
(a) In vitro cdk2 and cdk4 kinase assay of p16Ink4a-/-; p18Ink4c-/- MEFs 
after 24 hour treatment with varying concentrations of PD 0332991.  
Cdk2 or cdk4 complexes were immunoprecipitated and kinase activity 
was assessed against GST-pRb-769 substrate (top).  One-sixth of the 
immunoprecipitated cdk2 or cdk4 was used as a loading control 
(bottom).  Note that more protein (900μg vs. 100μg) was used for cdk4 
immunoprecipitation than for cdk2 immunoprecipitation.  “NP” 
denotes no primary antibody. “NS” indicates no Rb substrate. 
(b) Ki67 staining of pancreatic islets, pituitary, lymph nodes, small bowel 
of 26 week old p16Ink4a -/-; p18Ink4c -/- mice.  Mice were treated with 
vehicle (top) or 150mg/kg PD 0332991 (bottom) for 2 weeks.  PL = 
posterior lobe, IL = intermediate lobe, GC = germinal center. 
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(Figure 10a).   
 To investigate the effects of cdk4/6 inhibition in adults, animals were treated with 150 mg/Kg of PD 
0332991 by oral gavage daily for two weeks. As previously reported (18), this dose and schedule were well 
tolerated by the mice without evident toxicity.  In accord with the phenotype observed in the p16Ink4a-/-; p18Ink4c 
-/- mice, both the pituitary and pancreatic islets showed a marked reduction in proliferation after treatment with 
PD 0332991 (Figure 10b).  Consistent with the reported hyperproliferation in germinal center B-cells in 
p18Ink4c-deficient animals (86), we found that the majority of proliferating cells in p16Ink4a -/-; p18Ink4c -/- lymph 
nodes express the B-cell marker B220, and not CD3, a T-cell marker (data not shown).  As was seen in the islet 
and pituitary, treatment with PD 033291 inhibited proliferation of these hyperproliferative B-cells in the 
germinal centers of lymph node (Figure 10b).  These data suggest that the pancreatic islet, intermediate 
pituitary, and germinal center B-lymphocytes require the catalytic activity of cdk4/6 for proliferation in adult 
mice. 
Unlike the islet and pituitary, however, proliferation in other tissues was not affected by prolonged 
cdk4/6 inhibition.  The high rate of proliferation seen in the small bowel was not changed after 2 weeks of PD 
0332991 treatment (Figure 1b).  In addition, a subset of B220-negative and CD3-negative cells dispersed 
throughout the lymph nodes continued to proliferate despite cdk4/6 inhibition (Figure 10b, Data not shown).  
The morphology, location and frequency of these cells appear most consistent with inter-digitating dendritic 
cells of the lymph node.  Although it is formally possible that PD 0332991 is excluded from certain 
proliferating compartments, a more likely explanation is that proliferation of some cell types in adult mice do 
not require cdk4/6 activity.   
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Discussion 
p16Ink4a and p18Ink4c cooperate to suppress tumorigenesis in mice 
 The elucidation of the redundant contributions of individual genes in a highly related family is a 
problem in the study of mammalian biology, particularly in the case of the Ink4 family of cdk inhibitors.  All 
four proteins are capable of binding cdk4 and cdk6 (22, 27, 29, 71), and there appears to be little biochemical 
distinction among the Ink4’s with regard to this activity (84).  Therefore, it is not surprising that there is 
significant compensation by remaining Ink4’s in MEFs singly deficient for p16Ink4a and p18Ink4c.  However, 
Ink4-null mice show marked phenotypic differences, indicating distinct roles for these proteins in vivo.  An 
examination of p15Ink4b -/-; p18Ink4c -/- (44) and p19Ink4d -/-; p18Ink4c -/- (92) mice has led to elucidation of some 
of the unique functions of Ink4 proteins, and we have expanded on this data through generation of mice lacking 
both p16Ink4a and p18Ink4c. 
 Our data suggests that p16Ink4a and p18Ink4c are important determinants of physiologic and neoplastic 
proliferation in certain tissues in vivo.  For example, p18Ink4c appeared to regulate homeostatic islet and pituitary 
proliferation in young mice, and this effect was constrained by p16Ink4a expression (Figures 5, 6a, 8b, 9b, and 
10b).  Loss of both proteins potently cooperated in pituitary tumorigenesis in our study; whereas the tumor 
spectrum, frequency, and latency in p18Ink4c -/- mice was not augmented by additional loss of p15Ink4b (44) or 
p19Ink4d (92).  Although high penetrance of lethal pituitary tumors limited the finding of new tumor types, the 
latency of lethal pituitary tumors in p16Ink4a -/-; p18Ink4c -/-  mice was much shorter than either single knock-out, 
with survival comparable to mice with cdk4R24C mutation, which does not bind Ink4 proteins (64, 78).  Analysis 
of Ink4 levels in several tissues suggested an explanation for the cooperation seen between p16Ink4a and p18Ink4c 
loss: only p16Ink4a expression was significantly increased in the pituitary of p18Ink4c-/- mice, and not p15Ink4b or 
p19Ink4d.  This compensation is not limited to the pituitary, where there was an obvious phenotype, but was also 
seen in other tissues to varying degrees, and in cultured MEFs (Figures 3b, 4b, and 4c).  These results suggest a 
potent feedback mechanism for regulating cdk4/6 in the response to increased kinase activity. 
 Control of p16Ink4a expression by Rb-family protein function has been noted in several systems where 
inactivation of Rb leads to a rapid increase in p16Ink4a expression (48, 82).  Likewise, p16Ink4a can be activated 
by over-expression of E2F (35), arguing for the presence of a feedback loop between Rb and p16Ink4a.  Clearly, 
however, physiologic proliferation with attendant Rb-family phosphorylation is not generally sufficient to 
activate p16Ink4a expression.  Instead, Rb loss only appears to activate p16Ink4a expression under specific 
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circumstances (e.g. neoplastic growth).  Recent work has suggested a possible explanation for the conditional 
regulation of p16Ink4a by Rb.  Polycomb group (PcG) protein Bmi-1, which durably represses of p16Ink4a 
expression in association with covalent histone modifications (31, 32),  is targeted to the Ink4a/Arf locus by Rb-
family proteins (7, 37).  Additionally, Bmi-1 appears to require Rb-family function to stably repress p16Ink4a 
expression in human and murine cells.  Interestingly, Bmi-1 also binds to and represses the Arf and p15Ink4b 
promoters in MEFs (7).  Therefore, it is tempting to speculate that p16Ink4a expression (and possibly that of 
p15Ink4b and Arf as well) is increased in certain p18Ink4c-deficient tissues because of a relative 
hyperphosphorylation of pRb with attendant decrease in the PcG-mediated repression of the Ink4a/Arf locus.   
 
Role of p16Ink4a in aging 
The expression of p16Ink4a has been shown to increase with aging in a variety of different human and 
murine tissues (41, 56, 93).  In particular, the pancreatic islets show large increases in p16Ink4a levels with aging 
in vivo (41, 56, 93) , and cultured human islets undergo telomere-independent senescence in the setting of 
p16Ink4a induction (26).  Additionally, mice lacking cdk4 or cyclin D1/2, which activate cdk4, are born with 
normal islet mass, but have reduced proliferation and islet mass as young adults (21, 42, 65, 87), while mice 
with increased islet cdk4 activity, due to p18Ink4c deficiency or activating mutations of cdk4 (61, 65), show an 
increase in islet mass.  We have shown that the age-dependent increase in p16Ink4a levels causes a functional 
decrease in islet proliferation.  Conversely, over-expression of p16Ink4a through use of a BAC transgenic 
significantly decreased islet proliferation even in young mice.  These data suggest p16Ink4a mediates a decline in 
the replicative capacity of islets associated with aging and, in this compartment, is both a biomarker and 
effector of aging.   
While we have shown that p16Ink4a functionally inhibits proliferation in the pancreatic islets, p16Ink4a 
expression increases in a variety of tissues (41, 93), suggesting that p16Ink4a may regulate other tissue 
compartments with aging.  Indeed this is true for at least two types of stem cells, neural stem cells (NSCs) and 
hematopoietic stem cells (HSCs), both which demonstrate a p16Ink4a-mediated decline in function with aging 
(33, 54).   These results from diverse systems suggest that p16Ink4a contributes to mammalian aging by limiting 
the self-renewal of regenerative cells in at least the bone marrow, brain and endocrine pancreas.   
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Certain adult tissues require cdk4/6 activity 
 Recent genetic experiments have suggested that MEFs can proliferate without cdk4 (65, 87), cdk6 
(50), or both (38, 50).  Conversely, cdk2 kinase activity is also dispensable in MEFs, as cdk2 -/- (6, 57) and 
cyclin E1-/-; cyclin E2 -/- (20) cells can proliferate in culture, albeit more slowly.  While cdk4/6 activity was 
not a major determinant of MEF proliferation, this was not true in certain tissues in vivo such as the 
intermediate pituitary, germinal center B-cells, and pancreatic β-cell.  In these tissues, the specific requirement 
of cdk4/6 catalytic activity was supported by our findings that genetic loss of p16Ink4a and p18Ink4c resulted in 
their increased proliferation, whereas acute pharmocologic inhibition abrogated their proliferation.   
 The dependence of pancreatic β-cells cells on cdk4 for proliferation appears restricted to post-natal 
mice, as cdk4 -/- mice are born with islets, but cannot sustain proliferation as the animal grows (65, 87).  
Conversely, loss of cdk4 regulation by p18Ink4c loss (61), p16Ink4a loss (40) or knock-in of cdk4R24C (64, 65, 78) 
results in aberrant proliferation in the pancreatic β-cells.  In aggregate these results indicate an exclusive role for 
cdk4 in the regulation of pancreatic β-cell proliferation in the adult mouse.  Additionally, some tissues are 
regulated both pre- and post-natally by cdk4/6.  We have shown that B-cells require cdk4/6 for proliferation in 
the adult animal, but they are also required in the developing embryo, as both cyclin D-deficient and cdk4/6-
deficient mice die with greatly reduced common lymphoid progenitors (38, 50).  Most importantly, cdk4/6 -/- 
and cyclin-D1/D2/D3 -/- mice show that the absolute requirement for cdk4/6 in development appears to hold in 
only a few select tissue compartments, as substantial development occurs in their absence (38, 50).  Our data 
using a specific pharmacological inhibitor of cdk4/6 inhibitor further these developmental observations to show 
that adult mice similarly only require cdk4/6 in a limited number of compartments, including B-cells, pituitary 
adrenocortotrophs, and pancreatic β-cells; compartments where p16Ink4a-/-; p18Ink4c-/- mice show the most 
marked phenotype.  
 In summary, we have shown that p16Ink4a compensates for p18Ink4c loss to regulate neoplastic and 
physiologic proliferation.  Additionally, by both pharmacologic and genetic approaches, we have shown that 
p16Ink4a and p18Ink4c function in vivo to constrain cdk4/6 catalytic activity in highly specific compartments.  The 
search for effective Cdk inhibitors has been hampered by lack of clarity over the best Cdk to target and the 
challenge of achieving appropriate levels of kinase selectivity (reviewed  in(12, 72)).  Our data demonstrate that 
cdk4/6 kinase activity is directly responsible for regulating proliferation of specific tissue compartments in adult 
mice, and thus help to predict the toxicity of specific cdk4/6 inhibitors.  Additionally, these data offer hope that 
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certain established cancers, for example those characterized by cdk4 mutation, cyclin D amplification or p16Ink4a 
loss, will also strictly require cdk4/6 activity for proliferation, and therefore respond to specific pharmacologic 
inhibition of these kinases. 
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Materials and Methods 
Knock-out mice   
 For analysis of p16Ink4a-/-; p18Ink4c-/- mice, animals were generated and genotyped as previously 
described for p18Ink4c (16) and p16Ink4a (75), and were N1 in FVB. Mice were housed and treated in accordance 
with protocols approved by the institutional care and use committee for animal research at the University of 
North Carolina.  Murine p16INK4a and p18Ink4c are located 18cM apart on chromosome 4, requiring a modified 
breeding scheme of crossing two double heterozygotes in cis or two double heterozygotes in trans to generate 
the colony.  For survival analyses, animals were examined three times per week.  Rare deaths of unknown cause 
(n = 5) were censored from tumor-free analysis, but their inclusion does not change conclusions.  Formalin-
fixed tissue samples were embedded in paraffin and stained with hemotoxylin and eosin at the UNC Center for 
Gastrointestinal Biology and Disease histology core facility by Katharine Thompson.  
  
BAC Transgenics   
 An RPCI-22 mouse BAC library (http://bacpac.chori.org/mouse22.htm) was screened using a p16Ink4a 
probe (RsaI & AccI fragment, 2.5 kb upstream to the ATG site) and a 64 Kb genomic clone containing exon 1α, 
exon 2 and exon 3 (of p16Ink4a), but not exon 1β (of ARF) or exons of p15Ink4b, was identified. For generating 
transgenic mice, purified BAC was linearised and injected into fertilized (C57/Bl6 X C3H) eggs at the UNC 
Animal Models Core Facility. Transgenic founders were detected by PCR primers specific for the vector region 
and by Southern blotting.  By Southern analysis, the transgenic allele (129/SvEv) could be distinguished from 
the endogenous C57Bl/6 allele because of a known restriction fragment length polymorphism in the p16Ink4a 
promoter region between these two strains, permitting identification of single copy integrants.  Eleven 
independent founder lines were generated, at least two of which were single copy integrants.  All experiments 
described in this work were performed using littermate progeny from a single-copy integrant transgenic line 
(p16Ink4a TG) demonstrating mean ~5-fold overexpression of p16Ink4a as determined by TaqMan in 
representative tissues from 26- and 84-week old mice and by IP-Western blotting.  The experimental cohort of 
p16Ink4a TG mice and littermate controls was generated after backcrossing two generations to C57Bl/6.  All 
animals were housed and aged in the UNC barrier facility on standard diet.  All animal work was approved and 
done in accord with the UNC Institutional Animal Care and Use Committee. 
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Islet Analysis   
 Experiments on islet proliferation with aging were performed on progeny from p16Ink4a+/- intercrosses 
that had been backcrossed six or more generations to C57Bl/6.  As p16Ink4a-deficient animals develop tumors 
with a median latency of 75 weeks (76), tumor-bearing animals were excluded from the analysis.  For analysis 
of islet proliferation with aging, pancreata were harvested and Ki-67 staining was performed as on littermate 
pairs (p16Ink4a+/+ and -/- or p16Ink4a TG and WT). For WT/TG young vs. old cohort N=6000 to 15,000 total islet 
cells comprising 31 to 127 islets were counted from 2 to 4 mice per genotype per age.  For p16Ink4a +/+ and 
p16Ink4a -/- young vs. old cohort, N=8,500 to 40,000 total islet cells comprising 18 to 157 islets counted from 2 
to 4 mice per genotype per age.  All experiments with comparisons to p16Ink4a-/-; p18Ink4c-/- mice were 
performed on mice that were generated as described above, and were N1 FVB.  For comparison of 35 week old 
wild-type, p16Ink4a-/-, p18Ink4c-/- and p16Ink4a-/-; p18Ink4c-/- islets, 2 to 4 mice per genotype of wild-type (N=42 
islets) and p16Ink4a-/-; p18Ink4c-/- (N=52 islets) littermates and p16Ink4a-/- (N=58 islets) and p18Ink4c-/- (N=128 
islets) littermates were used due to linkage between p16Ink4a and p18Ink4c.  Islet size was determined by 
photographing 117 to 219 islets from 2-3 mice for each genotype, and analyzing with Image-Pro express 
software.  As islet proliferation and islet size were not normally distributed, all statistical comparisons were 
made using a non-parametric (Mann-Whitney) test.    
 
Cell Culture   
 Murine Embryo Fibroblasts (MEFs) were cultured from whole 13.5 day old embryos as described (75) 
and grown in 21%O2.  Cumulative population doublings were calculated as log2 (number of cells at 
harvest/number of cells plated) (13).  High density seeding was done as previously described (74).  Briefly, cells 
were plated at 1.27x104 cells/ cm2 with duplicate samples from 4-6 lines of each genotype.  Plates were re-fed 
every two days, but not passaged, and total cell number was assessed after 21 days.  Transformations with H-
RasG12V and SV-40 TAg were performed as previously described (74) with duplicate samples from 4-6 lines of 
each genotype.   
 
RNA preparation from islet and exocrine pancreas and qRT-PCR    
 Islets and exocrine pancreas were isolated from young (12-14 week) and old (64-80 week) mice by 
collagenase digestion followed by separation through centrifugation on a density gradient, as previously 
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described in detail (55).  RNA isolation, reverse transcription and TaqMan Real-time PCR were performed as 
described elsewhere (41)  with the exception that reverse transcription was performed using random hexamer 
rather than oligo-dT primer and more sensitive primer/probe sets specific for p16Ink4a and Arf were used (40).  
18S rRNA was used as a loading control for all reactions.  Primer sets for 18S (Hs99999901_s1), p15Ink4b 
(Mm00483241_m1), p18Ink4c (Mm00483243_m1), p19Ink4d (Mm00486943_m1), p21Cip1 (Mm00432448_m1), 
and p27Kip1 (Mm00438167_g1) were purchased from Applied Biosystems. 
 
Western blotting  
 Western blot assays were performed as described (76).  Briefly, cells were lysed in RIPA buffer 
(200mM Tris-HCl pH 7.4, 100mM NaCl, 10% glycerol, 0.5% SDS, 1% Triton X-100, Roche complete Mini-
tabs -1 tablet/ 10ml, Calbiochem Phosphatase inhibitor cocktail set I and II -1:100) for 30 minutes at 4oC, 
centrifuged for 10 minutes at 13 x g, supernatant was kept, and total protein was determined by colorimetric 
assay (Bio-Rad).  Protein was loaded onto 4-12% or 10% Bis-Tris NuPAGE mini-gels (Invitrogen) and run in 
NuPAGE MES running buffer (Invitrogen).  Protein was transferred onto PDVF membranes (Millipore) and 
probed with antibodies against p16Ink4a (M-156, Santa Cruz), p19Arf (Ab-80, Abcam), Actin (C-1, Santa Cruz), 
Cyclin D1 (DCS-6, Cell Signaling), Cyclin E (M-20, Santa Cruz), cdk2 (M2, Santa Cruz), cdk4 (C-22, Santa 
Cruz).  Antibodies to p15Ink4b, p18Ink4c and p27Kip1 have been previously described (16, 17).  Antibody against 
p19Ink4d was raised against a C-terminal peptide, and affinity purified.  Protein levels were visualized using 
Enhanced ECL reagent (Amersham).   
 
IP-Kinase assays  
 Kinase assays were performed on MEFs as described (53) with some modifications.  Briefly, fresh 
cells were lysed for 45 minutes at 4oC in NP-40 buffer (50mM Tris pH 7.5, 150mM NaCl, 0.5% NP-40, 
Phosphatase inhibitor cocktail I and II (Calbiochem).  100μg (cdk2) or 900μg (cdk4) total protein was 
immunoprecipitated with antibodies specified above.  Lysates were pre-cleared twice with 50μl protein A 
agarose beads, then immunoprecipitated for 12 hours at 4oC.  Beads were rinsed three times with cold NP-40 
buffer, then twice with cold kinase assay buffer (50mM HEPES pH 7.0, 10mM MgCl2, 5mM MnCl2, 1mM 
DTT, 5μM ATP).  Reactions were done in 30μl kinase buffer with 5μCi [γ-32P]ATP (3000Ci/mmol) and 1μl 
GST-Rb substrate (Santa Cruz, Rb769).  Reactions were carried out for 30 minutes at 30oC. SDS sample buffer 
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was then added, lysates were boiled for 3 minutes, and protein separated on 12.5% Bis-Acrylamide gels. 
Relative kinase activity was quantified using a Phosphor screen, STORM840 scanner and Image Quant 
software (Molecular Dynamics) 
 
IP-Western blotting   
 Tissues from p16Ink4a TG mice were homogenized and lysed in RIPA buffer (200mM Tris –HCl pH 
7.4, 130mM NaCl, 10% glycerol, 0.5% SDS, 1% Triton-X 100, 0.5% sodium deoxycholate).  Three mg of total 
protein was pre-cleared with 50μl Protein A agarose beads (Invitrogen), and cleared lysate was incubated 
overnight at 4oC with 2μg p16Ink4a antibody (M-156, Santa Cruz).  Lysate was incubated with protein A beads 
for 2 hours at 4oC.  Protein was separated on a 4-12% Bis-Tris mini-gel (Invitrogen) and transferred to 
Immobilon-P membrane (Millipore), then probed with α-p16Ink4a antibody (M-156).   
 
Immunohistochemistry  
 Assistance in sample processing was provided by the UNC Center for Gastrointestinal Biology and 
Disease and a commercial pathology lab (SR VetCheck).  Comparison of proliferation between genotypes was 
performed by calculation of the Ki-67 (MIB1) proliferative index using well-established methods within the 
clinical laboratory at the Brigham and Women's Hospital Pathology Immunohistochemical laboratory.  In brief, 
paraffin samples from indicated genetic backgrounds were fixed and processed in a uniform fashion. Five 
micron sections were cut and IHC staining for Ki-67 (Rabbit polyclonal, NCL-Ki67p, Novocastra) was 
performed using highly sensitive DAKO EnVision polymerized HRP detection methods. The proliferative 
index was calculated on a per islet basis as (Total Ki67+ islet cells)/(Total # of islet cells) per islet for each 
sample. Positive (human tonsil) and negative controls (primary antibody omission on human appendix) were 
performed during all analyses.  Staining for ACTH (DAKO - N1531); Prolactin (DAKO– N1549); Growth 
hormone (DAKO –L1814); Leutinizing hormone (DAKO- L1827); Follicle stimulating hormone (DAKO- 
L1810), B220 (BD Biosciences/Pharmingen  – 557390) or CD3 (Serotec – MCA1477) was performed using the 
same protocol. 
 
Drug Treatment   
 To assess proliferation after cdk4/6 inhibition, mice were treated daily for two weeks by oral gavage 
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with 150mg/Kg of 87.11mM PD 0332991 dissolved in 50mM Sodium Lactate buffer (pH 4.0), or buffer alone 
as described (18). 
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CHAPTER 4 
DISCUSSION 
 The study of proliferation in cultured cells offers many advantages over in vivo study.  These include 
the ability to tightly control the cells’ environment, regulate gene expression, perform biochemical analysis, and 
so forth.  However, a major drawback of cell culture experiments is distinguishing artifact from real in vivo 
processes.  This is clearly the case in the study of senescence and immortalization, where the in vivo relevance 
has been hotly debated (118).  That said, a great deal about the regulation of the cell cycle has been learned by 
combining both cell culture and mouse studies, and has lead to a clearer understanding of the processes at work 
in controlling when and if a cell divides.  Thus, we have used both in vitro and in vivo approaches to study the 
roles of cdk inhibitors in cancer and aging. 
 
Cdk4/6 activity in murine cells 
 Activation of p53 limits proliferation in human cells in both a telomere-dependent (2-4, 7, 8, 10, 24, 
37, 39, 55) and telomere-independent fashion (102, 110).  Expression of p16INK4a appears to be the dominant 
telomere-independent pathway for limiting cell proliferation, and increased expression of p16INK4a in human 
fibroblasts (1, 9, 13, 18, 89) and a variety of human epithelial cell types (12, 27, 56, 94, 105) has been strongly 
associated with the induction of senescence.  In addition, inducible expression of p16INK4a alone has been shown 
to cause permanent senescence (25), and recent data suggests that p16INK4a functions to enforce the permanence 
of senescence through generation of an ROS feedback loop and inhibition of mitotic exit (95, 125).  In addition, 
a variety of human cell types, such as myoblast and myeloma cell lines (6, 104),  mantle cell lymphoma lines 
(70), colon cancer lines (31), melanoma cell lines, and normal human fibroblasts (M. Ramsey, N. Sharpless, 
unpublished data) have greatly decreased proliferation upon inhibition of cdk4/6 with the pharmacologic 
inhibitor PD 0332991.  These data suggest that many human cell types that can be cultured rely heavily on 
cdk4/6 kinase activity for proliferation. 
 While the role of p16INK4a as an enforcer of senescence in vitro is clear in human cells, the role of 
cdk4/6 in murine cells has been less clear.  A few specific murine cell types such as macrophages (97) and  
 
melanocytes (124) have been shown to undergo p16Ink4a-mediated senescence, but loss of p16Ink4a has little 
effect on the proliferative lifespan of MEFs (58, 114), despite the high levels of p16Ink4a expressed in MEFs 
(137). Likewise, increased cdk4/6 activity due to loss of p18Ink4c (65), p19Ink4d (138), p18Ink4c and p19Ink4d (136) 
or p16Ink4a and p18Ink4c does not appreciably alter the lifespan of MEFs.  Additionally, in contrast to human 
fibroblasts, proliferation in MEFs is only modestly affected by cdk4/6 inhibition (M. Ramsey, N. Sharpless, 
unpublished data), and cdk4 kinase activity actually increases with serial passage reaching its peak at 
senescence (Figure 4c, d).  There are, however, some particular circumstances where cdk4/6 activity is 
important in MEF biology.  Lack of p16Ink4a allows MEFs to continue to proliferate in the face of high Arf 
expression, and escape senescence at higher frequency than wild-type cells (116).  In addition, p15Ink4b -/- and 
cdk4R24C MEFs (98, 121) demonstrate an increase in lifespan, suggesting that high levels of cdk4 can drive 
proliferation in MEFs, despite low activity of cdk2 at late passage.  It is interesting that p15Ink4b loss, but not 
p16Ink4a, p18Ink4c, or p19Ink4d deficiency can extended the lifespan of MEFs.  We have shown that p16Ink4a-/-, 
p18Ink4c -/-, and p16Ink4a-/-; p18Ink4c-/- MEFs have increased expression of remaining Ink4 proteins, resulting in 
only modest increases in cdk4 kinase activity, even in p16Ink4a-/-; p18Ink4c-/- MEFs.  It is possible that while we 
have seen transcriptional compensation for p16Ink4a and/ or p18Ink4c loss, this compensation does not occur in 
p15Ink4b-/- MEFs, leading to larger increases in cdk4 kinase activity.  We have also noted in p16Ink4a-/-; p18Ink4c-
/- MEFs that increases in cdk4/6 kinase activity correlate with decreases in cdk2 activity (M. Ramsey, N. 
Sharpless, unpublished data), although growth rate and lifespan do not change.  It is tempting to speculate that 
some cell types, such as MEFs, may have the ability to use either cdk2 or cdk4/6 to drive proliferation and 
therefore can switch from cdk2-dependent proliferation to cdk4/6-dependent proliferation based on the 
particular needs of the cell.    
 Despite this wealth of knowledge about control of proliferation by cdk2 and cdk4/6 in MEFs, there is 
very little known about other cell types.  While MEFs are most often used for knock-out studies due to their 
ease of growth, they represent a fairly undefined cell type with little known about their tissue(s) of origin.  We 
have shown that while MEFs are relatively unaffected by cdk4/6 inhibition, this should really come as little 
surprise, as only a few cell types require cdk4/6 for proliferation in the adult mouse.  It will be important in 
future work to use more purified cell types in vitro to clarify the roles of cdk2 and cdk4/6 in the regulation of 
proliferation of specific tissues in vivo, as well as the larger, organsimal context. 
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In vivo relevance of senescence 
 While the culture-based phenomenon of senescence is interesting, it is important to validate these 
findings in vivo.  Senescence has been suggested as a mechanism which limits proliferation in vivo, but 
evidence to support this has been largely indirect.  The components of the Rb and p53 pathways, crucial to the 
establishment of in vitro senescence are frequently mutated in human cancer (68, 88, 113), suggesting they are 
important in limiting in vivo proliferation.  In addition, Ink4a/Arf-/-(108, 116), p16Ink4a -/-(58, 114, 116), Arf-/-
(53, 54, 116), p53-/-(28, 38, 46), Rb+/-(43, 45), and cdk4R24C (98, 121) mice are all tumor prone, indicating that 
these proteins function to restrain proliferation in vivo.  While activation of these tumor suppressor pathways in 
vitro by overexpression of oncogenes such as Ras (90, 109) and B-Raf (135), also results in senescence, this 
does not prove that activated oncogenes induce senescence in vivo, or that this is a mechanism of tumor 
suppression.  After much debate on this topic, a group of recent reports have clearly shown that oncogene-
induced senescence does indeed occur in vivo in a variety of settings (11, 20, 23, 34, 81), establishing 
senescence as a bona fide tumor suppressor mechanism. 
 While the tumor suppressive function of senescence is clearly of benefit to the organism in that it 
blocks progression of cancer, what are the consequences of inducing permanent cell cycle arrest on normal 
tissue function?  To address this issue, we investigated the impact of p16Ink4a expression on proliferation of the 
pancreatic islet with aging.  In both mice (60, 137) and humans (78, 79, 87), p16INK4a levels have been shown to 
increase with aging in a variety of tissues.  The islets are of particular interest, because cultured human islet 
cells undergo p16INK4a-mediated senescence (36), and p16INK4a levels increase with aging in both human (87) 
and murine islets (60).  In addition, genetic experiments in mice have shown that perturbation of the cyclin D-
cdk4 complex, the downstream targets of p16Ink4a, affects islet proliferation in adult mice (33, 61, 69, 71, 99, 
130).  We have shown that p16Ink4a expression increases with aging in the islets, and plays a role in limiting 
proliferation of the islets with aging (Figure 8, (59)).  These data are supported by findings that p16Ink4a also 
limits proliferation in an age dependent fashion in the skin(101), in neural stem cells (86), and in hematopoietic 
stem cells (50).  It will be of great interest to determine what other specific tissue compartments show an age-
dependent decline in proliferation due to p16Ink4a expression, and how p16Ink4a is activated in these tissues.  A 
variety of stimuli have been reported to induce expression of p16Ink4a in culture, such as activating oncogenes 
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(90, 109, 135), DNA damage (103, 112), telomere dysfunction (47), and oxidative stress (19, 44, 125), however 
the mechanism of age-dependent p16Ink4a induction in vivo remains unclear.   
 It has been suggested that there exists a trade-off between blocking the progression of cancer through 
permanent cell cycle arrest, and maintaining adequate proliferative capacity to sustain prolonged tissue renewal 
(14, 15, 115, 117).  This concept has been difficult to prove, as aging studies on tumor suppressor genes are 
limited by the tumor-prone nature of knock-out animals.  A different approach using transgenic knock-ins of 
p53 (32) or p15Ink4b/p16Ink4a/Arf (73) seemed to contradict this theory, as the mice were less cancer-prone than 
wild-type cohorts, but had no significant change in lifespan.  The major caveats to these experiments are that 
lifespan is not a definitive measure of proliferative function in tissues, and that cancer resistance is not 
necessarily due to increased tumor suppressive activity, but may instead reflect the lower likelihood of mutating 
all three copies of the gene as opposed to the normal two copies in wild-type mice.  We (Figure 8, (59) and 
others (50, 86) have addressed these issues by investigating the effects of p16Ink4a on proliferation in specific 
tissues with aging, and demonstrating a p16Ink4a-dependent decline in proliferation with aging.  These data 
firmly establish the opposing actions of p16Ink4a in contributing to aging through its tumor suppressive 
functions. 
 
Therapeutic uses for cdk4/6 inhibition 
 Deregulation of the Rb pathway is a characteristic shared by virtually all cancers (reviewed in (72)).  
As activation of this pathway is essential for the proliferation of cancer cells, the Rb pathway appears to be an 
attractive target for therapeutic intervention.  The cyclin-dependent kinases are the mechanistic driver of Rb 
activation and thus the most attractive target.  To this end, a variety of cdk inhibitors have been developed for 
clinical use, but have thus far had limited success and high toxicity (reviewed in (111)).  Roscovitine is a small 
molecule ATP analogue which inhibits the kinase activity of cdk1, cdk2, and cdk5 (16, 76), but also has other 
off target effects, such as interfering with RNA transcription (84, 67).  However, while Roscovitine does inhibit 
proliferation (63, 80, 132) or cause apoptosis (35, 83) in cell lines, and has shown efficacy in xenograft models 
(74, 100, 126), positive clinical data is limited.  Another cdk inhibitor, flavopiridol, inhibits cdk1 (16), cdk2, 
cdk4 (17), cdk9 (26) but has a variety of non-cdk targets (42, 51, 57, 77).  While flavopiridol effectively inhibits 
proliferation or causes apoptosis in a broad range of cancer cell lines (66, 92, 106) and animal models (5, 29, 
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41, 122), it has limiting toxicity when given in clinical trials (123).  In an effort to minimize these adverse side 
effects, yet still inhibit proliferation, more specific cdk inhibitors have been developed (127).  The high 
incidence of mutation in p16INK4a, a specific inhibitor of cdk4 and cdk6, in a variety of cancers (reviewed in  
(113)), made cdk4/6 inhibitors a logical choice.  PD 0332991 was developed to specifically inhibit human 
CDK4 and CDK6, and does so effectively at low doses with little inhibition of CDK2 (31, 128).  This drug 
clearly inhibits proliferation of a variety of cell lines, both in culture and in SCID models, and appears to have 
few off target effects(70) (6, 31).  We have used this drug to take these studies further and examine the effects 
of cdk4/6 inhibition on the normal in vivo proliferation of various murine tissues.   
 Somewhat surprisingly, we have found a very narrow spectrum of tissues and cell types affected by 
cdk4/6 inhibition.  Tissues most clearly affected by cdk4/6 inhibition are the pancreatic islet β-cells, pituitary 
adrenocorotrophs, and germinal center B-cells.  These results fit well with established human and murine 
genetic data which suggest that Ink4 proteins and cdk4/6 activity regulate islet (61, 69, 71, 93, 98, 99), pituitary 
(40, 49) and B-cell (30, 129) proliferation.  Our data take this one step further, and show that the Ink4 proteins 
directly regulate the kinase activity of cdk4 and cdk6.  These results predict that loss of p16INK4a seen in a 
variety of human cancers will directly increase cdk4/6 kinase activity, and thus lend support for the clinical use 
of PD 0332991 as a cancer therapeutic for diseases such as pancreatic and esophageal cancer which have 
extremely high incidence of p16INK4a loss(113).  In addition, we have found that PD 0332991 has the added 
benefit of having minimal effect on proliferation of most tissues, such as the small bowel, even after long (2 
week) treatment,  a time where flavopiridol has been shown to induce gastric toxicity  (107).  
 We have investigated the efficacy of PD 0332991 in two different endogenous models of cancer in an 
effort to confirm data in vitro and in SCID models (31).  Treatment of a small cohort of p16Ink4a-/-; p18Ink4c -/- 
mice has suggested that cdk4/6 inhibition may be a viable strategy for some cancers, as the three mice that were 
treated for 6 weeks showed evidence of stable disease or regression.  However, upon withdrawal of the drug, 
mice quickly relapsed and died.  This response is reminiscent of the relapse kinetics seen in CML when patients 
were taken off imatinib therapy (82), suggesting that PD 0332991 may arrest, but not kill a progenitor cell 
population that drives this particular cancer.  Genetic evidence using kinase-dead cyclin D1 mutant mice has 
also suggested that cdk4/6 inhibition may be effective in ErbB-2-overexpressing tumors (64, 133).  In contrast, 
use of PD 0332991 in tyr-RasG12V; Ink4a/Arf -/-(22) mice to treat melanoma, a cancer with frequent p16INK4a 
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mutation (52, 96), had no measurable affect on tumor progression (M. Ramsey, K. Petermann, N. Sharpless, 
unpublished data).  In aggregate, these data show that the ability of cdk4/6 inhibitors to block cancer 
progression will likely be highly context dependent. 
 While the studies presented here focused on tissues which showed a hyperproliferation upon p16Ink4a 
and p18Ink4c loss, we have embarked on a more extensive study of tissues affected by cdk4/6 inhibition in an 
effort to more clearly understand the tissue specific use of cdk4/6 and to anticipate other possible side effects of 
PD 0332991.  One cell type which might be susceptible to cdk4/6 inhibition is the neural stem cell (NSC).  As 
we have shown in the pancreas, NSCs exhibit a decline in proliferation with aging, which is clearly p16Ink4a 
dependent (86).  In addition, loss of Bmi-1, a known repressor of p16Ink4a (48) significantly impairs the self-
renewal ability of NSCs, and this effect can be rescued by p16Ink4a loss (85).  Thus, it appears that NSCs may 
rely on cdk4/6 for proliferation, and may be affected by PD 0332991.  Another cell type of interest is the 
hematopoietic stem cell (HSC).  Like NSCs, HSCs also seem to be tightly regulated by the Ink4 family of 
proteins.  Genetic loss of p18Ink4c has been shown to increase the total size of the HSC compartment (134),  and 
as mice age, there is an increase in p16Ink4a in the HSC compartment which leads to decreased proliferative 
ability (50).  Like NSCs, loss of Bmi-1 leads to the loss of self-renewal capacity of HSCs (91).  We anticipate 
that treatment of mice, as well as humans with PD 0332991 will inhibit proliferation in these compartments, but 
it is likely that the effects will be reversible. 
 These data suggest that caution should be taken with long-term cancer therapy using PD 0332991, or 
other cdk4/6 kinase inhibitors.  Short-term therapy using PD 0332991 may indeed be a highly effective method 
of treating certain cancers, such as mantle cell lymphoma, which appear to be critically dependent on CDK4 
kinase activity (70).  However, our data suggests that long term therapy may leave patients susceptible to a 
variety of diseases due to impaired proliferation in B-cells and T-cells.  While this complication may be an 
impediment to the use of PD 0332991 as a cancer therapeutic, it may lead to the use of PD 0332991 as a 
chemoprotectant.  Many of the currently used cancer therapies, such as radiation, result in acute and chronic 
damage to the hematopoietic system.  Modulation of proliferative kinetics of various components of the 
hematopoietic system have long been in use to help lessen these toxicities (131), and inhibition of CDK4/6-
dependent proliferation may prove to be effective in this regard.  While these studies identify some of the 
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immune cells affected by cdk4/6 inhibition, a broad survey of all immunological cell types is necessary to 
determine cdk4/6 dependence and ability to proliferate after cdk4/6 inhibition. 
 In summary, this work has made a variety of novel contributions to understanding the complex 
mechanisms of proliferative control at the G1-S transition.  I have demonstrated that Ink4 proteins regulate 
proliferation through direct inhibition of cdk4/6 kinase activity, in stark contrast to the previously held beliefs of 
indirect, non-catalytic regulation(21, 62, 75, 119, 120).  The direct inhibition of cdk4/6 by Ink4 proteins is 
functionally relevant in adult murine tissues, as specific tissue compartments require cdk4/6 kinase activity for 
proliferation.  In addition, I have demonstrated a robust compensation network among the Ink4 family of genes, 
which functions both in vitro and in vivo to limit proliferation in response to increased cdk4/6 kinase activity.  
These findings add a previously unappreciated level of complexity to the regulation of cdk4/6, and elucidate a 
novel functional link between oxygen and regulation of the Ink4a/Arf locus. 
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